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ABSTRACT  
Phosphatidylinositol 3-kinases (PI3Ks) are a family of lipid kinases that phosphorylate the 3-OH 
of the inositol ring of phosphoinositides and deregulation of this pathway has implications in many 
diseases.  The search for novel PI3K inhibitors has been at the forefront of academic and industrial 
medicinal chemistry with over 600 medicinal chemistry-based publications and patents appearing 
to date, leading to 38 clinical candidates and the launch of 2 drugs, idelalisib in 2014 and copanlisib 
in 2017. This perspective will discuss medicinal chemistry design approaches to novel isoform-
selective inhibitors through considering brief case histories of compounds that have progressed 
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either into clinical development or that have revealed new structural motifs in this highly 
competitive area of research.  
 
INTRODUCTION 
Phosphatidylinositol 3-kinases (PI3Ks) are a family of intracellular signal transducer enzymes 
possessing regulatory roles in critical cellular processes including cell growth, proliferation, 
differentiation, motility and intracellular trafficking. Specifically, these lipid kinases 
phosphorylate the 3-position hydroxyl group of the inositol ring of phosphatidylinositol.1 
Deregulation of the phosphoinositide 3-kinase (PI3K) pathway has been implicated in numerous 
pathologies such as: cancer, diabetes, thrombosis, rheumatoid arthritis, activated PI3K-delta 
syndrome (APDS) and asthma. The eight known family members are sub-divided into three 
classes, I, II, and III where class I PI3Ks have been the most extensively studied; the class I is 
further subdivided into IA (PI3Kα, β, and δ) and IB (PI3Kγ), based upon the types of regulatory 
subunits, with which the catalytic domains combine in the active heterodimeric forms. Class 1A 
PI3Ks mediate the signal transduction from receptor tyrosine kinases (RTKs), while PI3Kγ is 
principally activated by G protein-coupled receptors (GPCRs). PI3Kα and β are ubiquitously 
expressed whereas PI3Kδ and γ are present in the hematopoietic system, epithelial cells and the 
central nervous system (CNS). Genetic deregulation of PI3K activity (such as overexpression) 
has been implicated in cancer for all the class I PI3K isoforms. 2, 3, 4, 5, 6, 7 In addition, mounting 
evidence supports a role for inhibition of PI3Kα in diabetes, 8,9  PI3K in thrombosis therapy, 
10,11 PI3Kδ and PI3Kγ in both rheumatoid arthritis and asthma therapy 12, 13, 14 and PI3K for 
APDS.15–17,18,19 Further, increased PI3Kγ expression in fibroblasts and basal cells has been 
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implicated in idiopathic pulmonary fibrosis. 20 It should be noted though that apart from cancer 
therapy, none of the other indications have been clinically validated to date. 21 
Consequently, the selective inhibition of individual PI3K isoforms using small molecule ATP-
competitive inhibitors has been well documented as a promising therapeutic strategy to treat 
these conditions. This increasing validation of the role of PI3K in several diseases has seen an 
expansion of research outputs from Pharmaceutical companies and academic groups alike. This 
perspective examines the published recent chemical literature, concentrating on case histories for 
the design of PI3K inhibitors that have entered into clinical development, as well as selected 
examples of structurally diverse compounds. However, we should comment on the huge amount 
of medicinal chemistry-based patent disclosures within this time frame, with a total of 418 
chemical patents being published since 2012 alone. This clearly demonstrates the large medicinal 
chemistry effort being employed to discover new inhibitors of PI3Ks. The number of patent 
publications has been mirrored to a good degree by the number of medicinal chemistry 
publications (n = 192) that have been published within this corresponding time frame (Figure 1). 
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Figure 1. PI3K medicinal chemistry-based publications and PI3K chemical patents from 2012-
2018 - source SciFinder 
 
In order to understand mechanisms underlying the isoform selectivity of these inhibitors, ligand-
bound X-ray structures on isoform- and pan-selective class I PI3K inhibitors have been extensively 
studied. These results have revealed selectivity, mainly towards PI3Kδ, can be achieved by 
exploiting the conformational flexibility and sequence diversity of active site residues that do not 
contact ATP.22 In their pioneering work, Berndt et al. 23 suggested that inhibitors can be organized 
into three general classes through a consideration of their binding to the ATP active site, namely:  
(a) inhibitors that adopt a “propeller-shaped” conformation when bound to the enzyme leading 
to the stabilization of a conformation that opens a hydrophobic “specificity” pocket in the active 
site that is not present in the apo-structure of the enzyme – these are mostly PI3Kδ selective 
inhibitors  
(b) inhibitors that are essentially “flat” which are mostly pan-selective class I PI3K inhibitors 
that do not provoke such a conformational rearrangement  
(c) inhibitors which have a “distorted propeller-shape” when bound to the enzyme but do not 
open the “specificity” pocket, again these are these are mostly PI3Kδ selective inhibitors  
The ATP-binding pocket of the compounds discussed by Berndt et al. were shown to contact a 
core set of six residues in the ATP-binding pocket and, apart from the hinge residue Val827 in 
PI3K were invariant in all of the class I PI3K isoforms. Four regions within the ATP-binding 
pocket were shown to be important for inhibitor binding including: an “adenine” pocket (hinge); 
a “specificity” pocket; an “affinity” pocket and the hydrophobic region II located at the mouth of 
the active-site (Figure 2).  
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Figure 2. The ligand bound X-ray crystal structure of IC87114 in PI3K showing the essential 
hinge binding interaction of Val828 and the specificity and affinity pockets as well as the 
hydrophobic region II (PDB 2X38) visualized in PyMOl.24 
 
As well as searching for isoform-specific PI3K inhibitors, many groups have investigated dual 
inhibition design and these approaches will be discussed in this perspective.25  
The major dual inhibitor approach is the search for compounds that inhibit both PI3K and the 
mammalian target of rapamycin (mTOR). The kinase mTOR is a member of the PIKK 
(phosphatidylinositol like kinase) family and is activated downstream of AKT leading to 
increased protein synthesis and growth. Analogs of rapamycin, which inhibit mTOR when 
complexed in part to rapamycin-insensitive companion of mammalian target of rapamycin 
(rictor, mTORC1 complex), have been approved for the treatment of advanced renal cell 
carcinoma, thus validating this target in humans.26 However, a potential limitation of exclusive 
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mTORC1 inhibition by such analogs is that the mTOR kinase can also participate in the 
mTORC2 protein complex, leading to activation of the oncogene AKT and, in doing so, promote 
cell survival through other signaling mechanisms.27 Therefore, to avoid this undesired feedback 
mechanism leading to potential resistance, ATP competitive mTOR kinase inhibitors that can 
inhibit both mTORC1 and mTORC2 have been pursued as alternatives to the rapamycin 
analogs.28 Given the quantity of evidence implicating both PI3K and mTOR in cancer, various 
groups have developed compounds that inhibit both kinases.  
This perspective will investigate the medicinal chemistry evolution of these inhibitor classes 
leading to clinical candidates (Table 1), as well as discussing new series of compounds grouped 
by chemical structure highlighting those that have progressed to deliver structurally diverse 
clinical candidates. 
Table 1. PI3K inhibitors progressed to clinical evaluation and development status as of July 2018  
Inhibitora Other names Primary indication Biological target Trial phaseb Company 
Alpelisib BYL719 oncology PI3Kα III Novartis 
AMG319  oncology PI3K II Amgen 
Apitolisib GDC-0980 oncology PI3K/mTOR Not 
progressing 
Genentech 
AZD8186  oncology PI3Kβ I AstraZeneca 
BGT226 NVP-BGT226 oncology PI3K/mTOR Not 
progressing 
Novartis 
Bimiralisib PQR309  oncology PI3K/mTOR I/II PIQUR 
Buparlisib BKM120 oncology Pan-PI3K III Novartis 
CH5132799  oncology PI3Kα Not 
progressing 
Chugai 
Copanlisib BAY 80-6946 oncology Pan-PI3K Approved Bayer 
CUDC-907 Fimepinostat oncology PI3KHDAC II Curacite 
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Inhibitora Other names Primary indication Biological target Trial phaseb Company 
Dactolisisb BEZ235  oncology PI3K/mTOR Not 
progressing 
Novartis 
Duvelisib IPI-145 oncology PI3K III Verastem 
GDC-0084  oncology PI3K/mTOR II Genentech 
Gedatolisib  PF-05212384; 
PKI-587 
oncology PI3K/mTOR II Pfizer 
GSK2292767  COPD/Asthma PI3K I GlaxoSmithKline 
GSK2636771  oncology PI3Kβ II GlaxoSmithKline 
Idelalisib  oncology PI3K Approved  Gilead 
IPI-549  oncology PI3Kγ I Infinity 
Leniolisib CDZ173 primary 
immunodeficiency 
disease 
PI3K III Novartis 
LY3023414  oncology PI3K/mTOR II Lilly 
Nemiralisib GSK2269557 COPD/Asthma PI3K II GlaxoSmithKline 
Omipalisib GSK2126458 oncology PI3K/mTOR I/II GlaxoSmithKline 
PF-04691502  oncology PI3K/mTOR Not 
progressing 
Pfizer 
Pictilisib GDC-0941 oncology Pan-PI3K II Genentech 
Pilaralisib SAR245408; 
XL147 
oncology Pan-PI3K II Sanofi/Exelixis 
RV-1729  COPD/Asthma PI3K I RespiVert 
Sapanisertib MLN0128; 
TAK-228;, 
INK128 
oncology mTOR II Millenium 
SAR260301  oncology PI3Kβ I Sanofi 
Serabelisib MLN1117; 
INK1117; 
TAK-117 
oncology PI3Kα II Takeda 
SF1126  oncology Pan-PI3K 
(prodrug) 
Not 
progressing 
SignalRx 
Sonolisib PX-866 oncology PI3K II Oncothyreon 
Taselisib GDC-0032 oncology PI3K / PI3Kβ-
sparing 
III Genentech 
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Inhibitora Other names Primary indication Biological target Trial phaseb Company 
Tenalisib RP6530 oncology PI3K II Rhizen-
Pharmaceuticals 
Umbralisib TGR-1202 oncology PI3K III TG Therapeutics 
Voxtalisib SAR245409;  
XL-765 
oncology PI3K/mTOR II Exelixis/Sanofi 
VS-5584  SB2343 oncology PI3K/mTOR Not 
progressing 
Verastem 
WX-037  oncology Pan-PI3K Not 
progressing 
WILEX AG 
ZSTK474  oncology Pan-PI3K Not 
progressing 
Zenyaku 
a For chemical structures see Supplementary material (Table ST1). b Source Fruman et al. 21, 
PubChem 29 
 
The propeller-shaped PI3K-selective inhibitors 
In 2006, a series of compounds were disclosed 8 describing a new class of PI3K compounds 
that existed in a “propeller-shaped” configuration. The class of compounds exemplified by 1 
(PIK-39) was more potent (>50-fold) towards the PI3Kδ isoform relative to the other class 1 
PI3Ks. This selectivity was attributed to the unusual overall shape of the molecules, as typical 
“flat kinase inhibitors” bound in the ATP-binding pocket with no significant difference in 
activity between the PI3K isoforms. It was considered, and demonstrated through X-ray 
crystallography 8 that the quinazolinone forces a key methionine (Met752 PI3Knumbering) that 
is conserved in all isoforms to move to accommodate the large quinazolinone group. This ligand-
induced fit confers a conformational shift in the peptide backbone leading to a conformational 
change in the ATP-binding region, enhancing isoform selectivity in favor of the PI3Kδ isoform 
(Figure 3). This unique binding mode has been the source of inspiration for many groups 
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involved in the search for selective PI3K inhibitors and a summary of key findings will be 
discussed here.  
 
Figure 3. Crystal structure of 1 (PIK-39) in PI3K demonstrating the propeller-shape 
conformation (PDB 2WXF) - visualized in PyMol. 
 
Idelalisib (2) was the first-in-class selective inhibitor of PI3K, which was approved by the 
FDA in 2014 for use with patients with chronic lymphocytic leukemia (CLL), focular lymphoma 
(FL) and small lymphocytic lymphoma (SLL). Idelalisib was initially discovered by Calistoga 
and was later advanced by Gilead and represented an important advance in the search for highly-
selective PI3K inhibitors.30 The European Medicines Agency (EMA), at the request of the 
European Commission, is currently reviewing idelalisib following concerns over serious adverse 
events in ongoing trials, mostly due to infections. TGR-1202 (3) a selective PI3K inhibitor, is 
currently undergoing Phase 2 Studies to assess the safety and efficacy in patients with CLL who 
are intolerant to prior Bruton Tyrosine Kinase (BTK) or PI3K inhibitor therapy. Duvelisib (4), a 
dual inhibitor of phosphoinositide 3-kinase PI3K and PI3K was shown to be clinically active 
in advanced hematologic malignancies and US FDA approval is currently being sought in both 
FL and CLL. In addition, a structural analog tenalisib (5), a dual inhibitor of phosphoinositide 3-
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kinase PI3K and PI3K recently obtained US FDA Fast Track Designations for treatment of 
relapsed/refractory peripheral T-cell lymphoma and relapsed refractory cutaneous T-cell 
lymphoma in addition to orphan-drug designations for treatment of peripheral and cutaneous T-
cell lymphoma. 
  
Unfortunately, to date there has been no journal publication detailing the discovery of 
idelalisib. However, the ligand-bound X-ray crystal structure (Figure 4) revealed the rationale for 
the observed high PI3K selectivity. Idelalisib binds in a similar conformation to 1 in the ATP 
binding site of the P110 catalytic subunit of PI3Kδ, with the purine forming two hydrogen bonds 
with key hinge residues (Val828 and Glu826).31 
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Figure 4. X-ray crystal structure of idelalisib bound to the ATP site of the P110 catalytic subunit 
of PI3Kδ showing the “propeller shape” adopted and the key hinge interactions with Val828 and 
Glu826 (PDB 4XEO) - visualized in PyMol.
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The fluorine containing quinazolinone ring assumes a perpendicular conformation to the hinge 
binder and is embedded in a specificity pocket between Trp760 and Met752 that is closed in the 
apo structure of the enzyme. The phenyl ring adopts a binding conformation perpendicular to the 
quinazolinone ring and protrudes into a hydrophobic region out of the ATP-binding pocket. The 
improved PI3Kδ selectivity of these “propeller shaped” compounds is proposed to be a 
consequence of the lower energy requirement for the creation of the specificity pocket in PI3Kδ 
relative to the other class 1 PI3K isoforms. The remainder of this section will concentrate on new 
medicinal chemistry disclosures based around the core structures of compounds 2-5 disclosed 
since 2012, highlighting key areas of SAR and learning from the original papers. 
Scientists at Gilead Sciences investigated the replacement of the hinge binding purine ring 
present in idelalisb, which was a known primary site of metabolism.32 The starting compound for 
their studies was 6, as this had a combination of good activity (PI3K IC50 = 1 nM) and good 
overall isoform selectivity (1200 ; 290 ; 55 ).33  
Scheme 1. Exploration of the hinge binding groups present in 2 (idelalisib) 
 
In their initial design, the purine was replaced with a series of substituted heterocyclic rings, 
maintaining the N-3 pyrimidine nitrogen and the 4-amino moiety which were believed to be 
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essential for activity (Scheme 1). Unfortunately, the structural modification led to a 100-fold 
drop in potency 7 (PI3K IC50 = 99 nM, selectivity >100 ; ; ). It was suggested that the 
loss in potency was due to the removal of the N-7 nitrogen of the purine ring which participates 
in a water-mediated hydrogen bonding interaction. In addition, removal of the 4-amino group 
resulted in a large drop in potency 8 (PI3K IC50 = 1700 nM). The potency and isoform 
selectivity was recovered through the introduction of a 5-cyano group 9 (PI3K IC50 = 8 nM), 10 
(PI3K IC50 = 0.4 nM, selectivity 4600 ; 200 ; 680 ) however, conversion to the 
pyridine analogue led to a drop-off in activity 11 (PI3K IC50 = 30 nM). Compound 10 was 
progressed to an in vivo metabolism study however, its clearance (1.1 L/h/kg) was 5-fold higher 
from its predicted clearance derived from in vitro microsomes, signifying the possibility of extra 
hepatic aldehyde oxidase (AO) metabolism. This was confirmed by the addition of the known 
AO inhibitor raloxifene in metabolism studies. In the presence of raloxifene there was very little 
turn over in human hepatocytes which was similar to that observed in human liver microsomes. 
In addition, metabolite identification demonstrated a major metabolite 12 (PI3K IC50 = 1500 
nM). Extensive structure activity relationship studies were initiated exploring modification of the 
pyrimidine ring to generate 13 (PI3K IC50 = 0.1 nM, selectivity 2200 ; 80 ; 60 hHeps 
(+ raloxifene )). This was followed by derivatization of the phenyl ring and 
replacement of the 2-chloro substituent with a fluorine atom to give 14 (PI3K IC50 = 2.2 nM, 
selectivity 1900 ; 650 ; 180 hHeps 0.34 L/h/kg). 
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Compound 14 offered a favorable combination of biochemical potency, isoform selectivity and 
metabolic stability. Additionally, when tested in a whole blood basophil cellular assay, 14 
inhibited PI3Kδ with an EC50 of 1 nM. In a KinomeScan screen against 395 non-mutant kinases 
14 displayed a high degree of kinase selectivity. When administered in vivo, 14 demonstrated 
low to intermediate total clearance in both rat (0.74 L/h/kg) and dog (0.58 L/h/kg), high volumes 
of distribution and high oral bioavailability (rat F = 106 ± 24%) and (dog F = 100 ± 40%), 
suggesting a good profile for target coverage at predicted trough concentrations after twice-daily 
dosing. Additionally, in a rat whole blood assay, 14 inhibited ex vivo anti-IgD stimulation of B 
cells with EC50 and EC90 values of 11 and 100 nM respectively. Therefore, 14 was progressed to 
a rat collagen-induced arthritis (CIA) model. In this model, dosing of 14 to rats with established 
CIA showed a significant and dose-dependent reduction in ankle swelling. In addition, a 
pharmacokinetic/pharmacodynamic (PK/PD) correlation between plasma concentration and 
efficacy was established. Although 14 proved a good compound for in vivo concept testing, it 
was still predicted to require twice-daily dosing and so Gilead scientists explored further 
refinement to reduce clearance and improve half-life.34 A correlation had been shown between a 
reduction of calculated lipophilicity (cLogP) and predicted clearance in hHEPS.33 Replacement 
of the phenyl group present in 14 (cLogP = 3.0) with a pyridine ring gave 15 (cLogP = 1.6, 
PI3K IC50 = 0.6 nM), a compound with lower predicted clearance and excellent isoform 
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selectivity (selectivity 1720 ; 167 ; 120 hHeps = 0.34 L/h/kg). When dosed in rats, 15 
had a good overall PK profile (CL 1.5 ± 0.13 L/h.kg; Vss 1.9 ± 0.3 L/kg; t1/2 2.5 ± 1.4 h; F 42%). 
However, it was demonstrated that the pyridine-containing compounds degraded rapidly at low 
pH due to ring opening of the quinazolinone ring, mediated through protonation of the pyridine 
nitrogen. A strategy to reduce the basicity of the N-1 quinazolinone nitrogen by substitution with 
small electron withdrawing groups in the 5- and 8-positions on the quinazolinone ring resulted in 
16 (PI3K IC50 = 0.4 nM, cpKa 0.28), a compound with a reduced N-1 basicity compared to 15 
(cpKa 1.97). This change resulted in a 7-fold increase in chemical stability (T1/2 = 19 h) when 
measured at 40oC, pH 2. Further SAR through changing the methyl substituent to a cyclopropyl 
group afforded 17, which was selected as the pre-clinical development candidate as GS-9901 
(PI3K IC50 = 1 nM, selectivity 750 ; 100 ; 190 stability at 40oC, pH 2 T1/2 = 20 h, rat 
PK CL 0.43 L/h.kg; Vss 0.83 L/kg; F 57%).  
 
Further exploration to build PI3K potency into the PI3K-selective template was achieved 
through targeting the non-conserved PI3K Asp856 in the hydrophobic region of class 1 PI3Ks. 
This was achieved through incorporating an H-bond donor moiety on the phenyl ring (Figure 
5).35  
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Figure 5. Building on PI3Kinhibitor idealisib to generate the PI3Kinhibitor 21 
 
In their initial work they replaced the phenyl ring in idelalisib (2) with a 4-phenol group to 
give 18 (PI3K IC50 = 14 nM; PI3K IC50 = 2.7 nM; PI3K IC50 = 1600 nM; PI3K IC50 = 4300 
nM). This change led to a large increase in PI3K activity compared to 2 (PI3K IC50 = 18 nM; 
PI3K IC50 = 3700 nM; PI3K IC50 = 7500 nM; PI3K IC50 = 2100 nM), demonstrating that the 
concept of targeting the non-conserved Asp856 present in PI3K was correct, to increase PI3K 
activity. Further SAR studies demonstrated that the phenol could be replaced with a pyrazol-3-yl 
group 19 (PI3K IC50 = 0.6 nM; PI3K IC50 = 2.5 nM; PI3K IC50 = 82 nM; PI3K IC50= 990 
nM) with slightly improved physicochemical properties, although selectivity over PI3K was 
compromised. Unfortunately, the addition of the further H-bond donor groups dramatically 
decreased permeability 20 as well as decreasing metabolic stability. Further structural 
modifications afforded 21 (PI3K IC50 = 5.3 nM; PI3K IC50 = 7.8 nM; PI3K IC50 = 850 nM; 
PI3K IC50 >10000 nM; Caco-2 (AB / BA) 5.7 / 21.7 106 cms-1; rat PK CL 0.26 L/h.kg; Vss 0.52 
L/kg; F 66 ± 17%) as a potent and selective PI3Kinhibitor with good pharmacokinetic 
properties that demonstrated efficacy in a PTEN-deficient LNCaP prostate carcinoma xenograft 
tumor model. 
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Scientists at Amgen were also inspired by the rationalization of the PI3Kisoform selectivity 
imposed by the induced fit of the propeller-shaped compounds. In 2012 they reported the discovery 
and in vivo evaluation of a series of dual PI3Kinhibitors for the treatment of inflammatory 
diseases. A series of constrained and highly-substituted 4-aminoquinolines (e.g. 22 - 25) were 
prepared. After several rounds of SAR 22 (PI3K IC50 = 30 nM; PI3K IC50 = 58 nM; PI3K IC50 
= 3960 nM; PI3K IC50 = 2010 nM) became a promising lead. The addition of a pyridine ring led 
to a slight increase in activity and selectivity (PI3K IC50 = 7 nM; PI3K IC50 = 30 nM; PI3K 
IC50 = 1720 nM; PI3K IC50 = 92 nM). Replacement of the hinge binding morpholine with other 
heterocycles could be achieved, although PI3Kisoform selectivity was reduced e.g. 24 (PI3K 
IC50 = 3 nM; PI3K IC50 = 18 nM; PI3K IC50 = 510 nM; PI3K IC50 = 28 nM). The addition of 
a tetrahydropyran ring afforded a compound with enhanced water solubility, improved selectivity 
and good in vivo pharmacokinetics 25 (PI3K IC50 = 11 nM; PI3K IC50 = 44 nM; PI3K IC50 = 
3250 nM; PI3K IC50 = 509 nM, sol. (PBS) 146 mg/L, rat PK CL 0.8 L/h/kg; Vss 3.3 L/kg; F 
65%). Compound 25 was found to be efficacious in several inflammation models including a 
keyhole limpet hemocyanin study and a collagen-induced arthritis model.36 
Further investigation of this class of compound initially explored the linker group between the 
quinoline bicycle and the purine hinge binder (Figure 6).37  
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Figure 6. Discovery of the selective PI3Kδ inhibitor 33 (AMG319) 
 
Although 26 (PI3K IC50 = 0.24 M) was a reasonable starting point, the thioether was 
highlighted as a potential metabolic liability and SAR exploration revealed that the ether linkage 
27 (PI3K IC50 = 0.017 M) had higher enzymatic activity, whereas the methylene linker 29 was 
much less active (PI3K IC50 = 3.6 M). In addition, because of specific ligand-protein 
interactions, there was a demonstrable difference between the enantiomers 30 ((S)-enantiomer 
PI3K IC50 = 7.1 nM) and 31 (PI3K IC50 = 2.6 M) due to a steric clash between the (R)-
methyl and the protein.  Importantly, the amino linker 28 (PI3K IC50 = 0.041 M) had a similar 
level of activity to 27 which was mirrored in the preference for the (S)-enantiomer 32 (PI3K 
IC50 = 8 nM). Unsurprisingly, the compounds proved poorly soluble and had high microsomal 
instability displaying poor rat pharmacokinetics. Extensive SAR to optimize biological activity, 
isoform selectivity and CYP2D6 inhibition was achieved. Removal of the 8-methyl group and 
subsequent fluorination of the quinoline ring, in addition to substitution of the 2-aryl group with 
a 2-pyridyl group led to an increase in solubility and improvement in rat pharmacokinetics. The 
detailed SAR study eventually resulted in the identification of 33 (PI3K IC50 = 18 nM; PI3K 
IC50 = 2.7 M; PI3K IC50 = 33 M; PI3K IC50 = 0.85 M, sol. (PBS) 146 mg/L, rat PK CL 
0.34 L/h/kg; F 54%). Compound 33 had excellent activity in a whole blood assay (IC50 = 16 nM) 
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and selectivity over a large panel of kinases. In addition, 33 displayed a high level of in vivo 
efficacy as measured in two rodent disease models of inflammation and is currently being 
evaluated in phase 2 clinical trials for the treatment of human papillomavirus (HPV) and 
negative head and neck squamous cell carcinoma (HNSSCC). 
In a series of papers and patent disclosures, Amgen scientists demonstrated that the core 
quinoline scaffold present in 22-33 could be exchanged for a wide range of heterocycles38 in 
combination with exchanging the purine ring for other hinge binding motifs. The regioisomeric 
quinoline underwent extensive SAR studies exploring substitution at the quinoline 4-position, as 
typified by compound 34 (PI3K IC50 = 2.4 nM, rat PK CL = 0.057 L/h/kg; F 51%).39 In an 
additional publication, 40 exploration of the quinoline with a novel 4-carboxamide group 
generated compounds as typified by 35 (PI3K IC50 = 2.9 nM; rat PK CL = 0.51 L/h/kg; F 70%) 
and 36 (PI3K IC50 = 4.6 nM; rat PK CL = 0.42 L/h/kg; F 29%), with very high selectivity over 
the Class-1 PI3K isoforms 35 (6068 ; 979 ; 1217 ), 36 (3082 ; 478 ; 700 ). 36 
had selectivity against a panel of 442 protein kinases as well as excellent cellular potency in 
mouse B cells (pAKT IC50 = 0.7 nM and 0.8 nM respectively). Efficacy experiments in a key rat 
limpet hemocyanin model demonstrated that administration of 35 or 36 resulted in a strong dose-
dependent reduction in IgG and IgM antibodies, making the compounds suitable for pre-clinical 
development.  
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 In a final publication38 the quinoline core was exchanged for a substituted benzimidazole, 
resulting in the disclosure of two further pre-clinical candidates with good pharmacokinetic 
properties: 37 (PI3K IC50 = 16 nM; PI3K IC50 = 1.78 M; PI3K IC50 = 58.2 M; PI3K IC50 
= 5.8 M; mouse B cell (pAKT) IC50 = 4.6 nM; rat PK CL 0.93 L/h.kg; F 45%); and 38 (PI3K 
IC50 = 19 nM; PI3K IC50 = 2.33 M; PI3K IC50 = 27.2 M; PI3K IC50 = 5.9 M; mouse B 
cell (pAKT) IC50 = 4.2 nM; rat PK CL 0.99 L/h.kg; F 41%). The compounds inhibited B cell 
receptor (BCR)-mediated AKT phosphorylation (pAKT) in PI3Kδ-dependent in vitro cell based 
assays and were effective when administered in vivo at unbound concentrations consistent with 
their in vitro cell potency as a consequence of improved unbound drug concentration (0.36, 0.32 
respectively fraction unbound (rat)) with lower unbound clearance. In addition, the compounds 
demonstrated efficacy in a rat Keyhole Limpet Hemocyanin, where the blockade of PI3Kδ 
activity led to effective inhibition of antigen-specific IgG and IgM formation after immunization 
with KLH.  
Erra et al. reported on a series of selective PI3K inhibitors based on a pyrrolotriazine scaffold 
(Scheme 2).41 Moving the methyl group from the phenyl ring in 39 (PI3K IC50 = 130 nM) to the 
linker in 40 (PI3K IC50 = 75 nM) not only resulted in a slight increase in activity but also 
removed the potential for atropisomerism. Extensive SAR studies exploring the hinge binder, 
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linker and substitution on the pyrrolotriazine resulted in 41 (PI3K IC50 = 2.6 nM; PI3K IC50 = 
94 M; PI3K IC50 = 8.2 M; PI3K IC50 = 72 M; M-CSF-induced AKT in THP-1 cells IC50 = 
7.8 nM rat PK CL 1.4 mL/min/kg; Vz 1.2 L/kg ; F 98%) and entered clinical development as 
LAS191954 for the treatment of pemphigus.41 
 
Scheme 2. Discovery of 41 (LAS191954) through an extensive SAR exploration 
 
Wei et al. reported on the synthesis and evaluation of 5-alkynyl substituted quinazolin-4(3H)-
ones as selective PI3K inhibitors.42 Interestingly, they also reported on a series of analogs 
where the hinge binder is linked to the quinazolin-4(3H)-one via a 4- or 5-membered ring. The 
optimal compounds had good potency e.g. 42 (PI3K IC50 = 6.7 nM), 43 (PI3K IC50 = 7.1 nM), 
demonstrating that the incorporation of the ring linking group was not detrimental to biological 
activity. In addition, the compounds had good selectivity over PI3K (133-fold) and good 
cellular activity of IC50 = 37.2 nM and 58.9 nM in a SU-DHL-6 cell line challenge.     
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Evans et al. from Infinity Pharmaceuticals described the discovery of a series of selective 
PI3K inhibitors for the treatment of immuno-oncology diseases.43 Once again starting from the 
8-Cl isoquinolone core, a series of hinge binding groups were explored resulting in the discovery 
of a substituted pyrazolo[1,5-a]pyrimidine as a new hinge binding motif. Interestingly, this 
change resulted in a PI3K-selective inhibitor e.g. 44 (PI3K IC50 = 400 nM; PI3K IC50 = 40 
nM). Further SAR of the C-8 alkynyl substitution in 45 (PI3K IC50 = 700 nM; PI3K IC50 = 14 
nM) resulted in the discovery of 46 (PI3K IC50 >8400 nM; PI3K IC50 = 16 nM), a compound 
with very good mouse hepatocyte stability (T1/2 = 6 hours) and selectivity over other lipid 
kinases. In addition, 46 demonstrated favorable pharmacokinetic properties (mouse PK CL 3.6 
mL/min/kg; Vss 10.8 L/kg; F 88%) and showed robust inhibition of PI3K mediated neutrophil 
migration in vivo and is currently in phase 1 clinical trials in patients with advanced solid tumors 
as IPI-549 for a monotherapy or in combination with pembrolizumab (Scheme 3).     
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Scheme 3. Exploration of the hinge binding regions and introduction of a C-8 alkynyl substituent 
 
In the search for further new hinge binding motifs Srinivas et al. used the Huisgen 
cycloaddition reaction to synthesize a range of 1,4-substituted 1H-12,3-triazolo-quinazolin-
4(3H)-ones (Scheme 4).44 The chemistry resulted in the identification of a series of weak PI3K 
inhibitors e.g. 47 (PI3K IC50 = 5 M; PI3K IC50 = 430 M; PI3K IC50 = 250 M; PI3K IC50 
= 1 M). 
 
Scheme 4. Huisgen cycloaddition to generate a range of analogs such as 47 
 
Perry et al. disclosed the synthesis of soluble and cell-permeable PI3K inhibitors for long-
acting inhaled administration for the treatment of asthma (Figure 7).45 
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Figure 7. The incorporation of dibasic groups to improve lung tissue retention after delivery 
through inhalation  
 
The novel thiazolidinpyridone core was substituted to give 48, a potent and selective PI3K 
inhibitor (PI3K pIC50 = 9.4; PI3K pIC50 = 7.3; PI3K pIC50 = 6.2 M; PI3K pIC50 = 7.9). 
Unfortunately, the compound had modest solubility and had no detectable level in lung tissue 
when dosed through inhalation (i.t.). An X-ray crystal structure of 48 in PI3K revealed that 
substitution of the aryl group in the meta-position (group R) was favorable to position a potential 
solubilizing group into the exposed solvent. In light of this, a strategy was evolved to attach a 
(di)basic group to improve both the solubility and improve lung tissue retention. 46, 47 This 
resulted in 49 (PI3K pIC50 = 9.3), however this compound was not retained in lung tissue for 
sufficient time to have a pharmacodynamic effect. The addition of a dibasic group e.g. 50 (PI3K 
pIC50 = 9.3) and 51 (PI3K pIC50 = 9.2) gave compounds with excellent solubility and lung 
pharmacokinetic half-lives of 23.2 and 9.9 hours respectively. However, dibasic compounds 
generally exhibit poor cell permeability resulting in a decrease in activity from the isolated 
enzyme activity. Perry et al. describe the basicity and lipophilicity requirements required to 
balance lung tissue retention and cell permeability and suggested the overall driver of cell 
permeability was lipophilicity and concluded if log D is greater than ~1.6 then a compound with 
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a good enzyme activity will most probably have good cell potency and this was reflected in the 
cell-based potency of pIC50 8.0 and 8.9 respectively. 
The flat PI3K inhibitors 
 
In 2008, Folkes et al. from Genentech disclosed the synthesis and biological evaluation of a 
series of thieno[3,2-d]pyrimidines that demonstrate potent inhibition of PI3K⍺ culminating in the 
discovery of the pan PI3K inhibitor pictilisib 52 (GDC-0941).48 A crystal structure of 52 bound 
to PI3Kγ was obtained demonstrating a binding mode that many compounds in this perspective 
section share: the morpholine oxygen forms a pivotal hydrogen bond to the hinge region of the 
kinase via the amide of Val882 and the indazole moiety points towards the affinity pocket where 
the indazole nitrogen atoms make key interactions with the carboxyl group of Asp841 and the 
phenol oxygen of Tyr867.23 In addition, the 4-methanesulfonyl-piperazin-1-ylmethyl group 
extends out to solvent where the piperazine ring packs against the side chain of Met804, and the 
sulfonyl group oxygen atoms are within hydrogen bond distance of the side chain of Lys802 and 
the amide nitrogen of Ala805 (Figure 8). 
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Figure 8. X-ray crystal structure of 52 (GDC-0941) in PI3K (PDB 3DBS) visualized in PyMol. 
   
In their discovery, Genentech scientists utilized the thienopyrimidine 53 previously identified 
by Hayakawa et al. 49 which was shown to be potent against PI3K⍺ and showed significant anti-
proliferative activity in vitro. However, the PK profile of 53 was poor with a half-life of less than 
10 min after inter-peritoneal administration in mice and, at the onset of the project, Genentech’s 
scientists aim was to improve upon physicochemical properties, metabolic stability and potency 
of 53. 
Initially, the importance of the morpholine ring for P13K activity was shown when its 
substitution resulted in large reductions in potency, thus the morpholine group on all further 
derivatives was maintained.50 Methyl substitutions at the 6- and 7- position on the 
thienopyrimidine ring was investigated showing that 6-Me substitution 54 (PI3K IC50 = 6 nM) 
was well tolerated but 7-Me substitution showed a decrease in activity 55 (PI3K IC50 = 21 nM). 
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Effort was focused on the 6-position to block metabolism at this position. From the large range 
of active substituents, the addition of tertiary amines offering the potential for salt formation to 
aid kinetic solubility dissolution rates as well as in vivo absorption and tumor exposure proved 
promising. Of these, the piperazine analogs, such as 56 (PI3K IC50 = 10 nM), displayed 
enhanced metabolic stability in human and mouse microsomes (85 - 90%). However, they 
exhibited low bioavailability in mouse and rat (F = 0-11%) mainly due to glucuronidation of the 
phenol. This metabolic liability led to the exploration of bioisostere replacements using hydrogen 
bond donating heterocyclic groups. Ultimately, these changes led to the discovery of 52 (IC50 
PI3Kα = 0.003 µM, PI3Kβ = 0.033 µM, PI3Kδ = 0.003 µM, PI3Kγ = 0.075 µM, mTOR = 0.58 
µM). Acceptable oral bioavailability was achieved in all species tested including mouse (77%), 
rat (30%), dog (71%), and monkey (20%). 
Good levels of selectivity were observed for 52 when tested against members of PI3K classes 
II, III, and IV, including C2β (0.670 µM), Vps34 (>10 µM), DNA-PK (1.23 µM), and mTOR 
(0.58 µM). Additionally, 52 displayed outstanding selectivity for the PIK family kinases over a 
panel of 228 kinases in the Kinase Profiler panel from Millipore (formerly Upstate 
Biotechnologies). Only two kinases displayed greater than 50% inhibition at 1 μM. Flt3 
displayed 59% inhibition and TrkA displayed 61% inhibition by 52 μM, (IC50 2.85 μM). 52 
showed minimal inhibition of six of the principal cytochrome P450 isoforms and, at a 
concentration of 25 μM there was negligible induction of CYP1A and CYP3A4. There was also 
no significant blockade of the hERG channel (IC50 64 μM) in the patch clamp assay. 52 was 
progressed to in vivo studies and it was found that 52 exhibited a strong inhibitory effect on the 
growth of human U87MG glioblastoma xenografts in athymic mice (tumor growth inhibition of 
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83%). 52 progressed to phase I and II clinical trials but further studies have been not progressed 
at this time. 
 
In 2009, with increasing evidence of clinical need for a dual mTOR/PI3K inhibitor, Genentech 
scientists set out to build mTOR activity into 52. They used Piramed’s PI-103 (57) as a tool 
compound as it contained the morpholino-pyrimidine core and was known to inhibit mTOR and 
the PI3Ks. They aimed to improve clearance of the compounds whilst maintaining or improving 
on potency and solubility. Additionally analogs containing a methyl group on the 
thienopyrimidine core (54-55) showed that it was possible to inhibit both mTOR and class 1 
PI3Ks simultaneously.51, 52 
When the indazole group in 52 was replaced with 2-aminopyrimidine 58, a 20-fold increase in 
mTOR activity was observed (from 570 nM to 29 nM). However, this change didn’t dramatically 
change the proliferation potency. The microsomal stability data correlated well with in vivo data 
except in dog pharmacokinetic studies, where a methyl substitution on the core was required to 
improve dog clearance 59 (GNE-477, PI3Kα IC50 = 4 nM, mTOR IC50 = 21 nM).52 
However, these structural changes led to solubility issues and the design focus moved to 
improving compound solubility whilst maintaining the good biological and pharmacokinetic 
properties. This was achieved by considering changes to the solvent exposed sulfonamide. A 
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series of piperazine amides were prepared to maintain the neutral charge of the distal amine 
using both amino and hydroxy acids, with and without substitution at the 7-position to modulate 
metabolic stability (Scheme 5). 
 
Scheme 5. Chemical exploration of the piperizine group through amidation to deliver (S)-61 
(apitoloisib) 
 
 Amine-based analogs all had good potency 60 (PI3K IC50 = 1.0 nM, mTOR IC50 = 14 nM) 
and showed good improvement in solubility (1.0 mg/mL pH 6.5). However,bioavailability was 
poor (F = 6%). The alcohol-based amides, such as (S)-61 and (R)-61 showed much better PK 
properties giving reasonable solubility (0.084 mg/mL pH 6.5), low to moderate predicted human 
clearance (3.1 – 6.5 mg/min/kg), and good oral bioavailability (F = 77 – 100%). The enantiomer 
(R)-61 demonstrated reduced biochemical activity and increased microsomal stability than (S)-
61 and was chosen for further study due to its low predicted clearance in human (3.1 ml/min/kg), 
its low in vivo clearance in rat (15 ml/min/kg) and its high oral bioavailability (F% = 100%). 
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The in vivo profile of (S)-61 was characterized through PK studies conducted in several 
different species. Clearance was low (predicted Clh 33 mL/min/kg, Clp 9.2 mL/min/kg), PPB was 
low (71%), solubility was good (0.084 mg/mL pH 6.5) and the volume of distribution was 1.7 
L/kg. The maximum tolerated dose of (S)-61 was found to be 7.5 mg/kg and at this dose tumor 
stasis or regression was observed in PC-3 and MCF-7 neo/HER2 mouse xenograft models. This 
is likely due to the high cellular potency, low plasma clearance and relatively high free-fraction 
of the drug in vivo. (S)-61  was found to show a high degree of selectivity over off-target kinases 
even while maintaining dual inhibition of mTOR and the PI3K isoforms. This was confirmed by 
Invitrogen’s SelectScreen panel. Of the 240 kinases in the panel, only 5 other kinases 
consistently showed greater than 60% inhibition when treated with 1 µM (Fgr 697 nM, Mlk1 232 
nM, PAK4, Syk 134 nM, and Yes1). (S)-61 was highly selective over closely related PIKK 
family kinases: C2⍺ (1300 nM), C2β 794 nM, VPS34 2000 nM and DNA-PK 623 nM and (S)-
61 (GDC-0980, Apitolisib) was advanced into development and is currently in phase I and II 
clinical trials.51  
 
Having disclosed a pan-PI3K and a pan PI3K/mTOR inhibitor, Genentech scientists disclosed 
the development of a series of PI3Kδ-selective compounds 53 including 62 (PI3Kδ = 1.8 nM, δ/⍺ 
= 129, δ/β = 104, δ/γ = 1444) which used a 4-substituted indole as the phenol bioisostere 
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replacement. They hypothesized that, although the residues in the affinity pocket are highly 
conserved between the PI3K isoforms, disruption of the strong hydrogen bond between the 
indazole nitrogen atom and Tyr867, could radiate and extend past the conserved affinity pocket 
resulting in undesirable conformational changes for the anti-targets (α, β, γ), thereby providing 
PI3Kδ specificity when the indazole is replaced with an indole. Although this bioisosteric 
replacement led to improvements in selectivity they also observed dramatic differences in time-
dependent CYP3A4 inhibition, which could lead to auto-inhibition and poor drug-drug 
interactions. They employed several strategies to reduce this time-dependent inhibition to 
develop 63 (PI3Kδ = 12.3 nM, δ/⍺ = 50, δ/β = 815, δ/γ = 112). Unfortunately, they were 
unsuccessful in identifying an indole containing compound with the combination of reduced 
time-dependent inhibition, acceptable potency, selectivity and drug-like properties. 
 
After their previous programs that led to the discovery of 52 and (S)-61, Heffron et al.  
extended the study towards brain penetrant inhibitors.54 Compound 52 ([brain]u/[Plasma]u = 
<0.05), and (S)-61 ([brain]u/[Plasma]u = <0.05) were found to poorly penetrate the blood-brain-
barrier (BBB), which was attributed to efflux by the two most prevalent transporters in the BBB, 
P-glycoprotein (P-gp) and breast cancer resistance protein (Bcrp1). The properties of these 
compounds are markedly different from marketed drugs that target the CNS, where the median 
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values are: MW = 305, HBD = 1, TPSA = 45, and cLogP = 2.8. In order to bring these properties 
in-line with the median, they initially truncated the solvent exposed regions of the compounds, 
showing that the compounds retained biological activity. Additionally, using a central nervous 
system multi-parameter optimization (CNS MPO) scoring system (a score of 0-6) which was 
shown to display a correlation between higher CNS MPO score and low Pgp efflux, they 
prioritized the synthesis of compounds that have a CNS MPO score of  ≥4.5 for their study. Of 
the molecules they made prior to implementing an in silico evaluation, 53% had high efflux 
mediated by P-gp and 66% by Bcrp1. After employing the CNS MPO score of ≥4.5 as a filter, 
new compounds were more than twice as likely as those made before to have low efflux as a 
result of either P-gp or Bcrp1 transporters. This design strategy led to the discovery of 64 
([brain]u/[Plasma]u = 0.5, PI3K⍺ = 1 nM, mTOR = 10 nM) and 65 ([brain]u/[Plasma]u = 0.4, 
PI3K⍺ = 2 nM, mTOR = 9 nM). Both compounds were highly potent brain penetrant 
PI3K/mTOR inhibitors. Furthermore, compounds 64 and 65 were evaluated in a panel of 59 
kinases provided by Invitrogen’s SelectScreen service. Only 65 inhibited any kinase in the panel 
by >75% at 1 μM concentration of the test compound (PI3KC2β, 77%). 
By utilizing the highly-selective substituted indole group as a bioisostere for the phenol group, 
Sutherlin et al. reported a highly selective PI3Kδ compound, 66 (PI3Kδ = 3.8 nM, δ/⍺ = 340, δ/β 
= 200, δ/γ = 410). 55 Additionally, they reported that the methyl groups of the tertiary alcohol of 
66 could form hydrophobic contacts with the face of Trp760. This interaction would allow them 
to specifically target the space created by the Thr750 side chain in PI3Kδ, which is electronically 
and structurally distinct from the residues found in PI3Kα, β, and γ (Arg770, Lys771, and 
Lys802, respectively). This hydrophobic region present in PI3Kδ is often referred to as the 
“tryptophan shelf”. Compound 66 was progressed to in vivo studies in mouse and rat, and 
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showed moderate hepatic clearance (53 mL/min/kg and 59 mL/min/kg respectively). Reasonable 
half-lives were observed upon oral dosing (2.6 - 5 h and 2.6 - 4 h respectively) as well as good 
oral bioavailability (80% and 90% respectively). 
 
Murray et al. identified benzimidazole-based inhibitors of PI3Kδ with improved selectivity 
against other PI3K isoforms as well as improved in vitro and in vivo pharmacokinetic 
properties.56 They initially looked at modification of the central heterocycle, which they 
hypothesized would allow them to tune the interaction of the solvent region of the inhibitors with 
the “tryptophan shelf”. They explored a range of heterocyclic replacements and found that 
purines were interesting replacements for the thienopyrimidine, as these inhibitors were inactive 
against PI3Kγ and only weak inhibitors of PI3Kβ. The calculated ground state conformation of 
the purines indicated that a low-energy conformation is adopted in which the purine and 
benzimidazole rings are coplanar. Further optimization of PI3Kδ selectivity was achieved by 
increasing interactions with Trp760 through substitution of the solvent exposed group with 
alternative sterically demanding amines, compounds containing a hydrophobic groups attached 
to the piperazine ring, bulky amine groups and azetidines. Although substitution with the 4-
methanesulfonylpiperazine of 52 resulted in a significant increase in activity versus PI3Kα and 
PI3Kγ. 67 (PI3Kδ = 2 nM, δ/⍺ = 100, δ/γ = 260) is a representative example of the series; it is 
soluble in aqueous solution (sol. at pH 6.5 = 338 μg/mL) and has good permeability in a standard 
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MDCK assay (Papp = 16 × 10−6 cm/s). Rat (90%) and human (91%) plasma protein binding 
were moderate/good. There was no reversible or time-dependent CYP inhibition associated with 
67 in testing against five CYP isoforms. Additionally, very weak inhibition (less than 25% 
inhibition at 1 μM) was observed against a panel of 55 diverse kinases. Pharmacokinetic 
profiling of 67 indicated that it had moderate to low clearance, CL (rat) = 34 mL/min/kgand a Vss 
of 6.5 L/kg, and T1/2 = 2.6 h. 
Safina et al. reported 57 that inhibitors such as 67 were found to induce micronuclei formation 
in both the micronucleus test (MNT) and human chromosome aberration (HCA) assays in the 
absence of compound metabolism using the liver S9 fraction (-S9). However, it was determined 
to be non-genotoxic in the Ames test, suggesting that neither the MNT nor HCA result was 
directly linked to DNA mutation. They reported that genotoxicity SAR suggested that it was the 
combination of the purine core with the benzimidazole moiety that was responsible for the 
observed genotoxicity. Initially compounds that tested negative in the MNT assay were 
successfully identified through modifications of the molecular volume of the 2-benzimidazole. 
However, whilst they were exploring the conformational preferences required for selectivity 
towards PI3Kδ they simultaneously explored the effects of substitution and conformational 
restriction on genotoxicity. They designed analogs that altered the dihedral angle between the 
amine group and the purine N-7, mainly by substitution of the methylene carbon with 
heteroatoms. Through crystallographic and docking studies, the preferred dihedral angle was 
determined to be 10–30°. This led to the discovery of 68, where an isopropyl group increases the 
molecular volume of the 2-benzimidazole and an oxygen linker favors a torsional angle of <30°.  
68 tested negative in the HCA assay and exhibited excellent PI3K isoform selectivity (PI3K δ = 
0.47 nM, δ/⍺ = 256, δ/β = 420, δ/γ = 219) and broad kinase selectivity through Invitrogen’s 239 
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kinase panel at 1 µM, only B-Raf was inhibited at 61% and PI4Kβ at 71%. Additionally, 68 
possessed favorable pharmacokinetic properties with low predicted hepatic clearance in human 
(1.7 mL/min/kg) and moderate permeability (MDCK Papp A to B 8.23 x 10
-6) which led to high 
oral absorption across species (F = 82–100%) and acceptable half-lives (T1/2 = 2.59–11.6 h). 
Unfortunately, the series of thienopyrimidine containing brain penetrant PI3K inhibitors were 
deemed not suitable for clinical development due to projected poor metabolic human stability. 
With the knowledge that desirable metabolic stability was attainable with a purine scaffold they 
evaluated purine-based analogs of their previous thienopyrimidine series, ultimately resulting in 
69 (GDC-0084 PI3K⍺ = 2nM, mTOR = 0.07 µM). 69 exhibited excellent human metabolic 
stability in microsomal and hepatocyte incubations (CL (mouse) = 19 mL/min/kg) and had good 
oral bioavailability in mouse (F = 75%). 69 was shown to penetrate the BBB through 
determination of the brain-to-plasma ratio in mouse, where [Brain]u/[Plasma]u = 0.4. 
Additionally, 69 was studied in a subcutaneous U87 tumor xenograft model of glioblastoma in 
mice, showing a dose-dependent tumor growth inhibition. As a consequence, 69 was progressed 
to clinical development. 
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ZSTK474 (70) was discovered as a library hit by the Japanese Foundation for Cancer Research 
and showed strong anti-proliferative activity.58 However, its molecular target and therefore its 
potential as a novel anticancer drug was unknown at that time. They initially observed that the 
cellular potencies of 70 against a panel of cell-lines closely correlated with the cellular potencies 
of LY294002 (71) so they examined the ability of 70 to inhibit PI3K, observing that 70 was 20-
fold more active (PI3K⍺ = 8.9 nM, PI3Kβ = 17 nM, PI3Kγ = 53 nM, PI3Kδ = 16 nM) than 
LYS294002 (71) against PI3K and did not substantially inhibit the activity of 139 other protein 
kinases. 
In 2011, Burger et al. reported the identification of 72 (buparlisib, NVP-BKM120), (PI3K⍺ = 
52 nM, PI3Kβ = 166 nM, PI3Kγ = 262 nM, PI3Kδ = 116 nM). Their original hit came from a 
high throughput screen on a series of 2-morpholino 6-(3-hydroxyphenyl) pyrimidines identified 
from a solid phase combinatorial library of 2, 4, 6-trisubstituted pyrimidines in the same 
chemical class as 70.59, 60 After further modification the compounds per se had good oral 
bioavailability, low or sub-nanomolar biochemical potency and sub-micromolar cellular potency 
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against PI3K⍺, however had high clearance in rat. Their goal was to decrease clearance while 
maintaining and optimizing potency, solubility, permeability and safety. Initially improved 
clearance was achieved through substituting with an aminoquinoline in the solvent exposed 
region. In addition to increase potency they made substitutions in the activity pocket. In changing 
the pyrimidyl group to a pyridyl group they found that the biochemical potency increased upon 
the addition of an electron withdrawing group in the C-4 position of the pyridine, forcing the 
group out of plane to slightly improving aqueous solubility. This did not compromise the PK 
properties however, the compounds still exhibited low aqueous solubility and low Caco-2 
permeability. From previous work it was known that substitution of the C-4 position on the 
pyrimidine core could tolerate a wide range of moieties. Additionally, it was known that a 
morpholine group at the C-4 position of the core maintained reasonable potency while improving 
solubility relative to the aminoquinoline, and thus the aminoquinoline was substituted for a 
morpholine to give 72. The additional morpholine at the C-4 position did not compromise the rat 
PK parameters and solubility was improved.  
The biochemical activity of 72 was assessed across related lipid kinases and against more than 
200 protein kinases (VPS34 (2.4 µM), mTOR (4.6 µM), DNAPK (>5 µM), PIK4β (>25 µM)). 
No significant activity was observed against the protein kinases tested. The in vivo profile of 72 
was characterized through PK studies conducted in several different species including: mouse, 
rat, dog, and monkey. With the favorable cellular potency, kinase selectivity, pre-clinical 
pharmacology and rodent, dog and monkey pharmacokinetics, physical properties and preclinical 
safety profile, 72 was advanced into clinical trials in 2008. It was later reported that 72 exhibited 
an off-target activity at high concentrations that is not related to PI3K inhibition. This off-target 
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activity was found to be linked to mitosis and ultimately found to be due to inhibition of tubulin 
polymerization.61 
In order to overcome tubulin binding of 72, Bohnacke et al. from the University of Basel 
described the discovery of 73 (bimiralisib, PQR309).62  They reported the crystal structure of 72 
bound to tubulin (PDB 5M7E) and showed that high affinity binding of 72 to tubulin occurs via 
the pyrimidine core C–H group which is oriented towards βMet259 of tubulin. 73 was found to 
not bind to tubulin, which can be explained by the core C-H being replaced with a nitrogen atom. 
73 was found to be highly potent (PI3K⍺ = 15 nM, PI3Kβ = 11 nM, PI3Kγ = 25 nM, PI3Kδ = 25 
nM) and showed a satisfactory PK profile in vitro showing low clearance in rat, dog and human 
liver microsomes. 73 was progressed to in vivo studies in rodents and dogs, where it was found 
to be orally bioavailable and brain penetrable. The in vivo profile and a PC3 xenograft model in 
nude rats validated 73 as a clinical candidate and thus 73 was advanced through phase I clinical 
trials and is currently in phase II studies in relapsed and refractory lymphoma and advanced solid 
tumors. 
Zhang et. al., contrary to SAR studies conducted by Novartis and The University of Basel on 
the 4- and 6- positions, designed derivatives by replacing the C-2 morpholine with various 
aliphatic or long-chain substituted aromatic amines. Their work led to the discovery of 74 as a 
potent PI3K inhibitor (PI3Kα = 18 nM, PI3Kβ = 2014 nM, PI3Kδ = 13 nM, PI3Kγ = 80 nM) that 
showed comparable bioactivity with 70.63 
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The discovery of 79 (Gedatolisib, PKI-587 or PF05212384)64 by Wyeth (later Pfizer) followed 
on from the discovery of 75 (PKI-402).65 The initial lead compound was a triazolopyrimidine 76 
that exhibited good potency against PI3K⍺ (IC50 = 83 nM), PI3Kγ (IC50 = 435 nM), and mTOR 
(IC50 = 50 nM). However, activity, particularly against mTOR, and microsomal stability was 
improved by replacement of a benzylic alcohol with a substituted urea. The urea containing 
compound 77 was highly potent against PI3K⍺ (IC50 = 3.5 nM), PI3Kγ (IC50 = 24.8 nM), and 
mTOR (IC50 = 0.32 nM), however the compound exhibited very poor solubility. In order to 
increase solubility, basic amines were introduced onto the urea, giving compounds such as 75. 
However, solubility issues still persisted and advanced studies were halted until modifications to 
75 were implemented to decrease the overall lipophilicity of the series. In addition, another 
morpholine group was included to address a reported morpholine metabolic liability via 
oxidation ⍺ to the morpholine ring oxygen causing loss of potency. This morpholine change to 
the bismorpholino-1, 3, 5- triazine scaffold, such as 78, led to potent PI3K⍺, PI3Kγ, and mTOR 
inhibitory activity but only moderate potency in cell proliferation assays, attributed to poor 
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solubility and permeability. Due to the retention of biochemical potency, they probed the SAR to 
improve cellular potency. They observed a drop in PI3K activity when substituting the phenyl 
moiety of the urea with an alkyl group. However, the compounds maintained mTOR potency and 
incorporating basic amines onto the phenyl ring, as in the case of 79, led to excellent biochemical 
and cell potencies. These analogs had good microsomal stability across species and exhibited 
good to moderate solubility. On the basis of enhanced potency (PI3K⍺ = 0.4 nM, PI3Kβ = 6.0 
nM, PI3Kγ = 8 nM, PI3Kδ = 6 nM, mTOR = 1.6 nM), solubility (14 µg/mL pH 7.4), microsomal 
stability and a lack of Cyp inhibition, 79 was chosen for further in vivo evaluations, showing low 
plasma clearance (7 mL/min/kg), high volume of distribution (7.2 L/kg), and long half-life (T½ = 
14.4 h). 79 was also evaluated against a panel of 236 human protein kinases at 10 μM, where it 
was found to be highly selective for PI3K and mTOR. 79 progressed to phase I and II clinical 
trials. 
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Miller et. al. reported a series of inhibitors in the same structural class as 63, although they 
were consistently less potent.66 Compound 80 (PI3K⍺ IC50 = 375 nM, PI3Kβ IC50 = 214 nM, 
PI3Kγ IC50 = >10 µM, PI3Kδ IC50 = 110 nM) is representative of that series. Overall, they found 
that substitution in the 5-position was consistently ~10-fold more potent than substitution at the 
6-position. In a subsequent paper the morpholine in the solvent exposed region was replaced 
with piperazine amides derived from amino acids, 81 is representative of the series.67 They 
sought to form interactions with Asn836 of PI3Kδ to gain selectivity towards PI3Kδ but found 
that 81 was a β/δ inhibitor (PI3K⍺ IC50 = 2611 nM, PI3Kβ IC50 = 36 nM, PI3Kγ IC50 = 5859 nM, 
PI3Kδ IC50 = 12 nM). In a subsequent publication, Pinson et al. highlighted 82 as a compound 
with high PI3K isoform selectivity (PI3K⍺ IC50 = 4700 nM, PI3Kβ IC50 = 63 nM, PI3Kγ IC50 = 
>100 µM, PI3Kδ IC50 = 2200 nM) through targeting the non-conserved Asp862 on PI3K. 
Compound 82 showed strong inhibition of cellular Akt phosphorylation and growth of PTEN-
deficient MD-MBA-468 cells.68 
Also, in the same structural class are a series of inhibitors reported by Dugar et al. from 
Sphaera Pharma.69 Compound 83 was identified as their candidate compound for further 
development exhibiting good potency towards PI3K⍺ (IC50 = 60 nM) and good cellular potency 
(IC50 = 500 nM). 83 also showed a high level of microsomal stability, excellent oral 
bioavailability (AUC = 5.2 µM/h), no hERG liability and minimal inhibition activity for 
CYP3A4, CYP2C19, and CYP2D6 at 10 μM concentrations. Gamage et al. produced extensive 
SAR on analogs of 70, replacing one of the morpholine groups with a sulphonamide containing 
substituents lead to a series of PI3K inhibitors.70 Most compounds synthesized suffered solubility 
issues, however 84 (PI3K⍺ IC50 = 22 nM, PI3Kβ IC50 = 116 nM, PI3Kδ IC50 = 13 nM), as the 
methanesulfonate salt, showed suitable solubility (3.82 µg/mL) to be progressed in vivo. 
 41 
Compound 84 was evaluated in a mouse study using U87MG human glioblastoma tumor 
xenografts in Rag1-/- mice at a dose of 60 mg/kg qd x 10 by i.p. injection effectively slowed 
tumor growth over the 10 day dosing period. 
 
Ohwada et al. from Chugai Pharmaceutical Co. superimposed compounds 57 and 71. The 
structure based design led to a phenol and morpholine containing lead 85, which showed 
excellent activity (PI3K IC50 = 8.6 nM) but exhibited poor metabolic stability in human 
microsomes and poor oral bioavailability in mouse mainly due to rapid glucuronidation of the 
phenol.71, 72 They sought to address the metabolic instability through bioisosteric replacement of 
the phenol with an aminopyrimidine moiety, which showed a slight reduction in PI3K⍺ activity 
but exhibited good antitumor activity in vivo in a human prostate cancer PC3 xenograft model, as 
a result of improved metabolic stability and oral bioavailability. With room for improvement in 
terms of its physicochemical and ADME profile, they embarked upon modification of the solvent 
exposed region to ultimately lead to the discovery of 86 (CH5132799), a clinical candidate that 
showed good activity against PI3K⍺ (IC50 = 14 nM), good oral bioavailability in mouse (F = 
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101%), good human liver microsomal stability and in vivo antitumor activity in the PC3 
xenograft model (TGI: 101% at 25 mg/kg, 11 days). 86 selectively inhibits class I PI3Ks and 
showed less inhibition of class II PI3Ks (C2⍺ = >10 µM, C2β = 5.3 µM), class III PI3K (Vps34 
= >10 µM) and mTOR (IC50 = 1.6 µM) . Additionally, 86 showed no inhibitory activity (IC50 
>10 µM) against 26 other protein kinases. 
After the development of 86, Kawada et al. made changes to further improve the PK profile. 
The chemistry focused on introducing a solubilizing group in the solvent exposed region to give 
compound 87.73 Additionally, 87 incorporates an ortho-substituent which disrupts the molecular 
planarity and improves water solubility. The pharmacokinetic profile of 87 in mouse showed a 
good clearance (CL = 11.1 mL/min/kg) and oral bioavailability (F = 86%), without significant 
loss of inhibitory activity (PI3K⍺ = 42 nM).  
In a follow up paper, Kawada et al. from Chugai Pharmaceutical Co reported that the 
introduction of an urea functionality, as in the case of 88, enhanced PI3K⍺ activity (22 nM).74 
They proposed that this observation was due to the urea acting as a spacer, placing the aromatic 
ring close enough to the Trp760 to make a favorable interaction, thus enhancing the inhibitory 
activity. This change however introduced a solubility issue, due to intermolecular hydrogen 
bonding between the urea and the pyrimidine core, resulting in a flat conformation that increases 
the crystallization propensity. They attempted to disrupt the planarity by introducing a methyl 
group to the ortho-position on the amino-pyrimidine however, this led to an 8-fold reduction of 
potency as disrupting the planarity in this region of the inhibitor was not acceptable for keeping 
key interactions in the affinity pocket. They then shifted attention back to the urea region 
introducing ortho-substituents to the phenyl ring and including solubilizing amines such as ethyl 
piperazine. However,this was not enough to improve the solubility to a satisfactory level. 
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Incorporating an ortho-fluorine on the phenyl ring in which electrostatic repulsion between the 
fluorine atom and the urea carbonyl can be expected, resulted in a flat conformation and thus 
poor solubility. However, evaluation of the difluoro compound showed a modest increase to the 
solubility as this compound prefers a twisted conformation that avoids the electrostatic repulsion 
of the second fluorine atom with the urea carbonyl group. Liver microsomal stability of 88 was 
good in both mouse (7.6 µL/min/mg) and human (2.2 µL/min/mg) and permeability was also 
acceptable (1.1 x 10-6 cm/sec in PAMPA). 
 
Wang et al. from the Chinese Academy of Sciences utilized the structural information of 57 to 
design a series of 4-(2-arylpyrido[30,20:3,4]pyrrolo[1,2-f][1,2,4]triazin-4-yl)morpholine 
derivatives containing phenolic esters.75 The compounds had comparable PI3K⍺ activity to 57. 
All of the compounds showed selectivity over 15 protein kinases and anti-proliferative activity at 
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micromolar concentration against several cancer cell lines. An example of the series is 
compound 89 (PI3K⍺ IC50 = 33.6 nM). 
González et al. from the Spanish National Cancer Research Centre developed 90 (ETP-46321), 
employing a similar strategy to the Genentech team in the development of 52. Through a rational 
design exercise, they replaced the C-C unit between the pyrimidine ring and the thiophene with a 
C-N unit.76 In an effort to optimize potency and in vivo properties, they explored a variety of 
hetero-aromatic groups at the imidazo [1, 2-a] pyrazine C-6 position, leading to the discovery of 
90 (PI3K⍺ IC50 = 2.3 nM, PI3Kβ IC50 = 170 nM, PI3Kγ IC50 = 179 nM, PI3Kδ IC50 =14.2 nM). 
Compound 90 was shown to be a potent PI3K ⍺/δ inhibitor that was highly selective over mTOR 
(IC50 = 4.88 µM) and 288 representative kinases and demonstrated a good pharmacokinetic 
profile in mice (CL = 0.6 L/h/kg, F = 90%). Compound 90 was selected for preliminary in vivo 
evaluation in a lung tumor mouse model driven by a K-RasG12V oncogenic mutation and 
showed significant tumor growth inhibition (ca. 51%). In a later publication76 they applied a 
conformational restriction strategy to enable the exploration of the solvent-exposed region. 96 
(PI3K⍺ IC50 = 0.5 nM) is an example of the series and was progressed to a preliminary in vivo 
PK study and showed similar results to 90. Additionally González et al. reported a scaffold 
hopping strategy to replace the core moiety of 90 to produce compounds such as 97 (PI3K⍺ IC50 
= 1.52 nM, PI3Kβ IC50 = 155 nM).77  
With the goal of developing a dual mTOR/pan PI3K inhibitor, structure and ligand-based 
design was used to develop the lead structure 98 from 91 (VS-5584; SB2343). Using the SAR of 
compounds 57, 71 and 70, in combination with core modification, they developed a lead 
structure 98, possessing a purine core substituted with a morpholine ring, a phenol head group 
and a hydrophobic substituent.76 Compound 98 showed good potency against PI3K⍺ (IC50 = 89 
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nM) and mTOR (IC50 = 400 nM), however the phenol group posed a metabolic liability through 
glucoronidation. In order to overcome the metabolic liability, bioisoteric replacement of the 
phenol was employed resulting in substitution of the phenol for an amino-pyrimidine head group. 
The amino-pyrimidine head group was found to be equipotent with the phenol in inhibiting 
mTOR (300 nM) but introduced an imbalance in the inhibitory activity between mTOR and 
PI3Kα, being 10-fold more potent toward PI3Kα (IC50 = 34 nM). Optimization of the 8- and 9-
position side chains led to the discovery of 91, a compound with improved mTOR potency (IC50 
= 37 nM) and PI3K activity (PI3K⍺ IC50 =16 nM, PI3Kβ IC50 = 68 nM, PI3Kδ IC50 = 42 nM, 
and PI3Kγ IC50 = 25 nM). 91 was selected for further profiling and found to have excellent PK 
and ADME properties, as well as being active in animal models. 91 progressed to phase I trials 
in patients with advanced non-hematologic malignancies or lymphoma. 
Nacht et al. from Celgene Avilomics Research described 92 (CNX-1351), the first example of 
a targeted covalent inhibitor of the lipid kinase family that is an isoform-selective inhibitor of 
PI3Kα.78  After examining the ATP binding site and nearby residues of PI3Kα to identify 
opportunities for selective covalent modification they identified Cys862, which is unique to 
PI3K⍺, as a promising amino acid to target for covalent inhibition. Using the core of 52 in 
combination with a series of design cycles exploring both linker spacing and electrophilic 
functional groups they identified 92 and, although useful as a tool compound, the 
pharmacokinetic properties were suboptimal and thus they are currently focusing their efforts on 
improving the oral bioavailability. 
Saurat et al. described a series of dual mTOR/PI3K inhibitors based on a pyridopyrimidine 
scaffold that have nanomolar enzymatic and cellular activities with an acceptable kinase 
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selectivity profile. 93 (PI3K⍺ IC50 = 58 nM, mTOR IC50 = 5 nM) is a representative example of 
the series.79 
Starting from a morpholino-pyrrolotriazine heterocyclic lead, Dugar et al. from Sphaera 
Pharma Pte. Ltd developed their pre-clinical compound 94.80 94 (PI3K⍺ IC50 = 20 nM) was 
found to be inactive in a panel of close homology kinases, except for other isoforms of PI3K 
(PI3Kβ 54% inhibition at 1 µM, PI3Kδ 67% inhibition at 1 µM) and mTOR (85% inhibition at 1 
µM). 
Wang et al. described a series of compounds based on a quinazoline scaffold. 95 (PI3K⍺ IC50 
= 96 nM, PI3Kβ IC50 = 128 nM, PI3Kδ IC50 = 330 nM, and PI3Kγ IC50 = 465 nM) is 
representative of the series. 95 showed anti-proliferative effects in vitro and was found to induce 
apoptosis. Western blots suggested that 95 can block the PI3K/AKT/mTOR pathway. 
Additionally, 95 inhibited tumor growth on a mouse S180 homograft model.81 
 
Wang et al. synthesized a series of inhibitors based on a thiopyrano-pyrimidine core such as 
compound 99 (PI3K⍺ IC50 = 8.38 µM). These compounds showed cytotoxicity against four 
cancer cell lines (IC50 = 6.02–10.27 µM).82 In a later publication they incorporated the core from 
97 to produce a series of compounds, where 101 (PI3K⍺ IC50 = 1.25 µM) is representative of the 
series.83  
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Considering 52 as the chemical starting point, Schwehm et al. investigated the incorporation of 
a tricyclic molecular scaffold leading to the discovery of a series of potent and highly-selective 
PI3Kδ inhibitors.84 Compound 100 includes a 4-substituted indole group in the activity pocket, 
which was reported to give rise to good PI3Kδ selectivity.55 Additionally, they reported that an 
overlay of the available crystal structures of the class I PI3K isoforms reveals a potential key 
π−cation interaction present in the structures of the PI3Kα (Arg770), PI3Kβ (Lys771), and 
PI3Kγ (Lys802) isoforms with Trp760 (δ-numbering) that is not present in PI3Kδ (Thr750). 
They reported that this may suggest that their inhibitors might be able to form an extra Van der 
Waals π−π face to face interaction with Trp760, an interaction that is obstructed in the case of 
the other isoforms. These effects coupled together produced a synergistic group effect, to 
introduce high δ-selectivity. The physicochemical properties of compound 100 were calculated 
(PI3K δ (pIC50 = 9.1), MW 540.7, cLogP 3.9, clogD 2.5, TPSA 88 Å2, solubility at pH 7.4 in 
water: 0.02 mg/mL, solubility category: Low, LIPE = 5.2) and they report that the properties 
may not be ideal for oral drug likeness, however the compounds may fulfil inhalation delivery 
criteria.85 
The remainder of the perspective will examine the medicinal chemistry design and evaluation 
based on a core chemical structure categorized by scaffold class. 
Pyrrolo[2,1-f][1,2,4]triazin-4-amines  
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A novel series of pyrrolo[2,1-f][1,2,4]triazin-4-amines have been reported by researchers from 
Bristol-Myers Squibb, resulting in the identification of selective PI3K inhibitors. Bhide et al. 
reported on the identification of 102 (PI3K IC50 = 22 nM) from a kinase-directed screen.86 
However, 102 was shown to be non-selective against other PI3K isoforms (fold selectivity PI3K 
 = 4/120/0.4) and a potent CYP inhibitor which was attributed to the 4-pyridyl moiety as 
well as poor microsomal stability due, in part, to the lipophilic cyclohexyl ring. Extensive SAR 
aimed at changing the cyclohexyl group and the pyridine ring resulted in the identification of 103 
(PI3K IC50 = 2 nM, fold selectivity PI3K  = 665/800/130), a compound with improved 
metabolic stability (58% remaining @ 0.5 M 10 min incubation) and good pharmacokinetics 
(mouse PK CL 82.1 mL/kg/Kg; Vss 6.2 L/kg, F = 46%) that subsequently demonstrated in vivo 
efficacy in a mouse Keyhole Limpet Hemocyanin (KLH) and collagen-induced arthritis (CIA) 
model, when dosed at 100 mg/kg. The efficacy was reported to be better than that of 
methotrexate at 1mg/kg. Qin et al. reported on the optimization of the ADMET properties of the 
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compounds leading to the identification of 104 (PI3K IC50 = 1.3 nM, fold selectivity PI3K 
 = 611/1443/44), a compound with reduced hERG activity (18% @ 10 M – patch clamp) 
and metabolic stability. 104 progressed to a 4-day exploratory toxicity study in mice dosed up to 
300 mg/kg/day (QD) and was found to be well tolerated at all doses. In addition, 2 showed 
efficacy in the KLH model when dosed at 3 mg/kg, reflecting the improvement in whole cell 
potency and pharmacokinetic properties, compared to 103.87 Running in parallel, Marcoux et al. 
reported further SAR studies to improve the physical and pharmacokinetic properties of 104. 
Further exploration of the substituted piperazine and the replacement of the substituted pyrazole 
with smaller moieties resulted in the identification of the highly isoform-selective PI3K 
inhibitor 105 (PI3K PIC50 = <0.2 nM, fold selectivity PI3K  = >1000) that was highly 
potent in a human B cell proliferation assay (IC50 = 1 nM). In addition, 105 was shown not to 
inhibit any CYPS or ion channels. It possessed very good permeability but unfortunately 
exhibited poor stability towards liver microsomes where it was determined that the morpholine 
ring was extensively metabolized and was not progressed further.88 Liu et al. finally reported on 
the identification of a pre-clinical candidate 108 identified after further extensive SAR studies to 
improve on the pharmacokinetic properties within the evolving series. Guided by X-ray 
crystallography of 106 (PI3K IC50 = 2.4 ± 0.8nM, fold selectivity PI3K  = 270), in PI3K 
(Figure 9), the polar pyrazole group was replaced with either a simple chlorine atom or a 
trifluoromethyl group, which led to 107 (PI3K IC50 = 3 ± 1 nM, fold selectivity PI3K  
=110/37), a compound with improved Caco-2 permeability, reduced hERG activity (12% @ 3 
M – patch clamp) and increased selectivity profile, while maintaining potency in the CD69 
hWB assay.  
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Figure 9. X-ray co-crystal structure of 106 bound into PI3K Key interactions between 106 and 
the hinge included Val828 and Glu826 and a close interaction between the carbonyl of the 
acetamide group and Thr750. The pyrazole group of 106 filled a hydrophobic pocket formed by 
Ile825 (not shown) and participated in an edge-to-face interaction with Tyr813 (PDB 5VLR) 
Final optimization of the aryl substitution identified 108 (PI3K IC50 = 1.9 ± 0.9 nM, fold 
selectivity PI3K  =700/1443/>5000), where it was shown that the 4-CN group led to an 
improved human/rodent scaling in microsomal metabolic stability and excellent cross species 
pharmacokinetics (e.g. rat PK CL = 2.3 ± 0.3 mL/min/kg; Vss = 0.5 ± 0.1 L/kg; F = 71%). 108 
proved highly efficacious in a mouse collagen-induced arthritis model for 42 days. Although 
lower than expected exposures were observed for 108, a dose-dependent reduction of the clinical 
score was observed where doses of 2 and 5 mg/kg showed greater than 50% suppression of paw 
swelling. Taking the exposure into consideration, an EC50 of 10 nM at 24 h (ED50 of ∼1.25 
mg/kg) was derived.89  
Amino triazine-based hinge binders 
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Figure 10. Amino triazine-based hinge binders 
 
In a series of publications scientists from Amgen reported on the optimization of a novel series 
of substituted amino triazines culminating in the identification of 113 (AMG 511, Figure 10). In 
their first paper, Smith et al. discussed the optimization of a benzimidazole triazine 109 obtained 
from a HTS screen.90 109 had favorable properties (PI3K IC50 = 0.32 M; PI3K IC50 = 0.38 
M; PI3K IC50 = 0.24 M; PI3K IC50 = 0.1 M, mTOR IC50 = 0.097 M) and a co-crystal 
structure was determined in PI3K demonstrating that 109 bound in the ATP binding site. 
Optimization of 109 led to 110 (PI3K IC50 = 9 nM; PI3K IC50 = 5 nM; PI3K IC50 = 2 nM; 
PI3K IC50 = 4 nM, mTOR IC50 = 4.8 M), where the substituted piperazine was making 
interactions with the ribose pocket and the metabolically-labile 3-phenol was replaced with a 
substituted pyridine. 110 had good oral exposure in mice (F = 95%, 25 mg/kg p.o.) and inhibited 
HGF-stimulated PI3K signaling in a mouse liver PD assay where a 75 mg/kg dose was able to 
maintain sufficient plasma concentrations for 24 h to provide at least 64% target coverage over a 
24 h period (plasma free fraction concentration = 68 nM at 24 h). Subsequently, 110 caused a 
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dose-dependent inhibition of tumor growth with an ED50 of 6.0 mg/kg (AUC0–24 h = 7.6 μM/h) in 
CD1 nude mice and tumor stasis was achieved at 25 mg/kg QD. However, it was concluded that 
continuous robust inhibition of PI3K over 14 days may be poorly tolerated.91 Wurtz et al. 
reported on the hybridization of compounds; combining the amino triazines, such as 110 with a 
series of substituted aminobenzthiazoles 111 (PI3K IC50 = 1.2 nM; mTOR IC50 = 2.1 nM) 92 to 
generate 112 (PI3K IC50 = 7.7 nM; PI3K IC50 = 0.4 nM; PI3K IC50 = 2 nM; PI3K IC50 = 1 
nM, mTOR IC50 = 163 M), which exhibited good oral bioavailability in rats (F = 63%) and 
showed a dose dependent reduction in the phosphorylation of Akt in a U87 tumor 
pharmacodynamic model with a plasma EC50 = 193 nM.
93 Norman et al. reported on further 
optimization of 110 to identify 113, a potent pan inhibitor of class I PI3Ks with a superior 
pharmacokinetic profile (PI3K Ki = 4 nM; PI3K Ki = 6 nM; PI3K Ki = 2 nM; PI3K Ki = 1 
nM).94 113 was shown to potently block the targeted PI3K pathway in a mouse liver 
pharmacodynamic model as indicated by a dose-dependent decrease in phosphorylated AKT (p-
AKT) at Ser473 and a nonlinear regression analysis revealed a plasma EC50 of 228 ng/mL. It was 
shown that inhibition of AKT phosphorylation directly correlated with plasma concentrations. 
113 inhibit tumor growth in a U87 malignant glioma glioblastoma xenograft model where 
treatment at 1 mg/kg QD resulted in significant inhibition of tumor growth of approximately 
70% compared to the vehicle control group. Tumor stasis was observed in the cohort treated with 
3 mg/kg, and tumor regression was observed in the 10 mg/kg cohort. The ED50 of compound 113 
was 0.6 mg/kg, with an AUC at EC50 of 3.6 μg·h/mL. On the basis of its excellent in vivo 
efficacy and pharmacokinetic profile, compound 113 was selected for further evaluation as a 
clinical candidate. However, to date no further information has been reported. 
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In a subsequent paper, Lanman et al. reported on studies to replace the piperazine sulfonamide 
portion of 113 with an array of primary alcohols to reduce molecular weight and improve 
interaction within the ribose binding pocket, leading to the identification of 114 (PI3K Ki = 23 
nM), a compound with much reduced MWt compared to 113 (327 Da for 114 vs 518 Da for 
113). 114 demonstrated a similar pharmacokinetic profile to that of 113 with oral bioavailability 
slightly reduced (37% vs 57%) and clearance elevated (1.1 vs 0.45 L/h/kg). 114 was further 
evaluated in a mouse liver pharmacodynamic model that measured the inhibition of hepatocyte 
growth factor (HGF)-induced Akt phosphorylation at Ser473 in female CD1 nude mice and it 
significantly suppressed PI3K signaling at 10 and 30 mg/kg bringing about a dose-dependent 
decrease in p(S473)Akt. A nonlinear regression analysis established an EC50 of 239 ng/mL, 
comparable to that obtained from compound 113 (EC50 = 240 ng/mL). The biological activity of 
the significantly truncated analog 114 relative to 113 highlights both the efficiency of the 2-
hydroxypropyl group as a ribose pocket binding group however, compounds from this class were 
unable to replicate the enzymatic potency of the piperazine sulfonamide series.95 Stec et al. 
investigated the use of the imidazo[1,2-a]pyridine ring system as a scaffold and identified 115 as 
a potent dual phosphoinositide-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) 
inhibitor (PI3K Ki = 11 nM; PI3K Ki = 17 nM; PI3K Ki= 0.6 nM; PI3K Ki = 5.3 nM) 
mTOR IC50 = 206 nM). When dosed orally in rats (2 mg/kg), 115 showed good oral 
bioavailability (51%) and moderate plasma exposure (AUC = 640 ng·h/mL). The in vivo activity 
of compound 115 was evaluated in the mouse liver pharmacodynamic assay and showed 
significant inhibition of AKT phosphorylation at all three doses with a maximum inhibition of 
56% at the 30 mg/kg dose. The calculated ED50 relative to vehicle was 11 mg/kg.
96  
2,3-Dihydroimidazo[1,2-c]quinazolin-5-yl)pyrimidine-based inhibitors (copanlisib) 
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Scheme 6. Discovery of 119 (copanlisib) a PI3K inhibitor with potential antineoplastic activity 
 
Scott et al. recently reported on the identification of 119 (copanlisib), a selective 
PI3Kinhibitor that has been granted an accelerated approval as a treatment for patients with 
relapsed follicular lymphoma who have received at least 2 least prior systemic therapies (Scheme 
6).97, 98 HTS on a series of PI3Kγ‐active leads led to the discovery of the structurally novel 2,3‐
dihydroimidazo[1,2‐c]quinazoline 116 (PI3Kγ IC50 = 810 nM, PI3Kβ IC50 = 4000 nM). In the 
lead optimization phase, the enol moiety of 116 could be replaced with an amide moiety giving 
117 (PI3Kγ IC50 = 60 nM, PI3Kβ IC50 = 1 nM) and further substitutions on the phenyl ring led to 
118 (PI3Kγ IC50 = 60 nM, PI3Kβ IC50 = 1700 nM) and both were shown to have an effect on 
isoform selectivity. Therefore, a program to optimize the PI3Kβ and PI3Kα activity of the 2,3‐
dihydroimidazo[1,2‐c]quinazoline lead for potential use in cancer therapies was undertaken. 
Scott et al. reported on extensive SAR studies where multiple substitutions on the A ring in 
combination to changes in the B and C rings eventually led to the discovery of 119 
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(copanlisib).97 An X-ray crystal structure showed that the imidazoline N-1 nitrogen atom formed 
a critical hydrogen bond to Val882 in the adenine hinge pocket and the 4-aminopyrimiding group 
interacted in the affinity pocket forming hydrogen bonds with Asp836 and Asp841 through the 
amino group, and with Lys833 through a pyrimidine nitrogen atom (PDB 5G2N).  Copanlisib 
was shown to be a potent PI3K inhibitor (PI3K IC50 = 0.5 nM, PI3K IC50 = 3.7 nM, PI3K 
IC50 = 6.4 nM, PI3K IC50 = 45 nM) as well as inhibiting mTOR (IC50 = 45 nM) and has potent 
cellular mechanistic activity, inhibiting both IGF‐1‐stimulated AKT phosphorylation in S473 
cells, and basal AKT phosphorylation in KPL4 cells. The intravenous first-in-human phase I 
study of copanlisib in patients with advanced solid tumors and non-Hodgkin's lymphomas 
(NHL) showed that it was well tolerated with a MTD of 0.8 mg/kg. Copanlisib exhibited dose-
proportional pharmacokinetics and promising anti-tumor activity, particularly in patients with 
NHL.99 
4,6-Disubstituted indazole-based inhibitors (GSK2269557 & GSK2292767) 
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Scheme 7. Identification of 120 and the evolution to 122 (GSK2269557) and 124 (GSK2292767) 
 
Down et al. reported on the discovery of a series of selective indazole-based PI3K inhibitors for 
the treatment of respiratory diseases, culminating in the discovery of the development compound 
122 (GSK2269557) and the back-up clinical candidate 124 (GSK2292767) (Scheme 7).100 
Compound 120 was selected as a lead due to its favorable selectivity profile for PI3K (PI3K 
pIC50 = 7.0; PI3K pIC50 = 5.2; PI3K pIC50 = 5.0; PI3K pIC50 = 5.2) and, to avoid any 
potential negative impact of broad systemic inhibition of this biology, a lead optimization 
program was initiated with the aim of delivering an inhaled clinical candidate.  Inhibition of 
PI3K enzymatic activity was determined using a homogeneous time-resolved fluorescence 
(HTRF) assay format and to measure cellular activity for compounds of interest. In addition, a 
peripheral blood mononuclear (PBMC) assay was used using cytostim to stimulate cytokine 
production from the T-lymphocyte compartment. Interferon γ (IFNγ) was selected as an optimal 
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analyte owing to robust stimulation by cytostim and exquisite sensitivity to PI3Kδ inhibition. 
The target profile was established of high potency, which is a requirement for inhaled delivery 
due to dose limitations and the target PK profile was intended to minimize systemic circulation 
after inhaled delivery. Therefore, moderate to high intrinsic clearance was required in order to 
ensure removal of drug once absorbed through the lung into the plasma and low oral 
bioavailability was required to limit absorption of the swallowed fraction of the inhaled dose. 
Exploration of the SAR at the two positions of substitution on the indazole core was examined, 
where initially group R2 was fixed as indole and exploration of R1 pursued. A set of 4-position 
amide modifications were prepared while keeping the 6-indole substituent fixed. Extensive SAR 
showed that in this position a planar amide conformation was important for potency and isoform 
selectivity, as typified by 121 (PI3K pIC50 = 7.3; PI3K pIC50 = 5.0; PI3K pIC50 <4.6; PI3K 
pIC50 = 5.4). The requirements for planarity to balance both isoform potency and 
pharmacokinetics led to the application of heteroaromatic bioisosteric replacements for the co-
planar amide substitutent R1, leading to the eventual discovery of 122 (PI3K pKi = 9.9; PI3K 
pKi = 5.8; PI3K pKi = 5.3; PI3K pKi = 5.2), a compound with excellent cellular activity 
(PBMC IFN pKi 9.7). The rat PK profile of 122 was encouraging, with low oral bioavailability 
(F = 2%) and in vivo clearance of 28 mL min–1 kg–1, which met the criteria for progression. 
Importantly, due to the dibasic nature of 122 in combination with its moderate lipophilicity 
(clogP = 4.4), 122 also had a high volume of distribution of 6.3 L/kg, which suggested a 
beneficial tissue retention when delivered topically to the lung. 122 was progressed to a human 
lung parenchyma assay where finely chopped lung tissue was incubated with the plant lectin 
phytohemagglutinin (PHA) for 72 h to induce production of cytokines including IFNγ and IL-2. 
This response was inhibited by 122 in a concentration-dependent manner, returning pIC50 values 
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of 8.2 (IFNγ) and 8.1 (IL-2). In a disease relevant brown Norway rat acute OVA model of Th2 
driven lung inflammation, 122 was shown to protect against eosinophil recruitment, with an 
ED50 of 67 μg/kg. In addition, the activity of 122 was assessed using other end points in this 
model, including leukocyte recruitment to the lung (neutrophils, macrophages, CD4 and CD8 T-
lymphocytes at 48 h) and Th2 cytokines such as IL-13. Importantly, 122 was shown to dose-
dependently reduce recruitment of all leukocyte sub-populations and IL-13 in the lungs. In light 
of all the data, 122 progressed to clinical evaluation as GSK2269557. In phase I studies, inhaled 
GSK2269557 had an acceptable safety profile for progression into larger studies in COPD 
patients and resulted in suppression of sputum IL-8 and IL-6 levels, consistent with the known 
anti-inflammatory activity of a PI3Kδ inhibitor and further clinical trials are on-going.101 
Replacing the indole in 121 with a pyridyl methylsulfonamide gave 123 (PI3K pIC50 = 8.7; 
PI3K pIC50 = 6.0; PI3K pIC50 = 6.5; PI3K pIC50 = 7.3). Although this replacement resulted 
in a greater than 10-fold increase in potency for PI3Kδ, potency at the other PI3K isoforms was 
also significantly enhanced, such that compound 123 was no more selective than compound 121. 
However, further evolution of the sulfonamide group and bioisosteric replacement of the 
secondary amide resulted in 124 ((PI3K pKi = 10.1; PI3K pKi = 6.2; PI3K pKi = 6.3; PI3K 
pKi = 6.3), with excellent cellular activity (PBMC IFN pKi = 9.2). In a human lung parenchyma 
assay, 124 inhibited both IFNγ and IL-2 production in a concentration-dependent manner, with 
pIC50 values of 8.7 and 8.5, respectively. In the brown Norway rat acute OVA model of Th2 
driven inflammation in the lungs, 124 was shown to protect against eosinophil recruitment with 
an ED50 of 35 μg/kg, similar to compound 122. A PK study in rat, demonstrated a high in vivo 
clearance of 50 mL min–1 kg–1 which was significantly higher than that for compound 122 and 
fitted well for the target profile for a follow-up inhaled candidate. In addition, the oral 
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bioavailability was low (F < 2%), in line with the data observed for compound 122 and therefore 
124 was progressed into preclinical development as a back-up for 122.  
1,3-Dihydro-2H-imidazo[4,5-c][1,5]naphthyridin-2-ones (BEZ235) - inspired inhibitors 
 
Starting from 125 (BEZ235, dactolisib),61 the first PI3K inhibitor to enter clinical trials in 2006, 
Chen et al. from Pfizer reported on a fast-follower approach to discover 126, which exhibited 
excellent properties (mouse PI3K Ki = 1.41 nM, which translates to a ligand efficiency (LE) of 
0.354). When tested in an mTOR kinase domain in vitro biochemical assay, 126 exhibited good 
activity with a Ki of 4.51 nM. However, in a BT20 cell assay, measuring inhibition of AKT 
phosphorylation at S473, 126 exhibited only moderate cellular potency with an IC50 of 144 nM, 
which relates to a cell-based LipE of 2.15, due to high lipophilicity (cLogP 4.69). 
Unsurprisingly, the combination of lack of sp3 atoms and lipophilicity led to the reported poor 
solubility (2.0 M). 102 SAR studies, directed to increasing both PI3K and mTOR activity 
whilst reducing lipophilicity led to the discovery of 127 (PF-04979064), as a structurally diverse 
back-up to their first development compound 79.64 Compound 127 (PI3K Ki = 0.3 nM; mTOR 
Ki = 1.42 nM) and, due in part to the reduction in lipophilicity (cLogP = 1.27) and increase in 
solubility (539 M), had very good cellular potency (IC50 = 9.1 nM), which relates to a cell-
based improved LipE of 6.8. 127 progressed to pharmacokinetic studies (rat PK CL = 19.3 
ml/min/kg; Vdss = 5.23 L/kg; F = 61%) and progressed to mouse in vivo xenograft efficacy 
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studies, where it exhibited dose proportional tumor growth inhibition (TGI) in a U87MG mouse 
xenograft model, achieving 88% TGI at the highest tolerated dose, 40 mg/kg QD. 
2,8-Disubstituted pyrido[3,2-d]pyrimidine and substituted 5,6,7,8-tetrahydropyrido[4,3-
d]pyrimidine inhibitors (leniolisib) 
 
Hoegenauer et al. from Novartis also used 125 as a starting point for the discovery of 131.103 In 
their first disclosure they reported on efforts to synthesize a PI3K inhibitor. Guided by docking 
studies they deconstructed the imidazolquinoline present in 125, which they considered was 
contributing to the affinity of 125 for mTOR (mTOR IC50 = 6 nM), to the simplified quinazoline 
fragment 128 (PI3K IC50 = 0.65 M; PI3K IC50 = 8.1 M; PI3Kand mTOR IC50 = >10M). 
Further SAR studies led to 129 (PI3K IC50 = 0.262 M; PI3K IC50 = 9 nM; PI3KIC50 = 1.65 
M; PI3K IC50 = 4.63 M, cell activity PI3K IC50 = 0.049 M). In rats, 129 showed a moderate 
22% oral bioavailability. While a higher total exposure could be reached with increasing the dose 
to 30 mg/kg, this overall gain was not dose-linear and bioavailability dropped to 10%, likely due 
to solubility limited absorption. However, in dogs the overall pharmacokinetic properties for 129 
were similar but with a better 42% oral bioavailability at 0.3 mg/kg. PK/PD studies were performed 
in rodents following a single oral dose of compound 129 (30 mg/kg) in male Lewis rats. Blood 
was collected at various time points and changes for two PD biomarker expression profiles as well 
as drug levels were determined. A clear relationship of drug exposure, inhibition of Akt 
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phosphorylation and anti-IgM/rIL-4-induced CD86 expression was observed.104 Further SAR was 
reported by Hoegenauer et al. to improve physicochemical properties of the quinazoline  series, as 
typified by 129, through reducing the MWt and fsp3 which are known drivers of poor 
physicochemical properties. Further SAR studies resulted in the identification of 130 (PI3K IC50 
= 0.424 M; PI3K IC50 = 22 nM; PI3KIC50 = 1.03 M; PI3K IC50 = 2.94 M). However, the 
improvement in physicochemical properties did not lead to an increase in cellular activity (IC50 = 
0.022 M), due in part, to the reduction in PI3K activity.105 In their final publication, further 
optimization led to the discovery of 131 (leniolisib PI3K IC50 = 0.244 M; PI3K IC50 = 11 nM; 
PI3KIC50 = 0.424 M; PI3K IC50 = 2.23 M). 131 demonstrated 30-fold cell activity over 
PI3K (PI3KIC50 = 56 nMwas tested in a mouse ozone-induced lung inflammation model 
where it dose-dependently inhibited the increase in bronchoalveolar lavage (BAL) neutrophil and 
macrophage numbers with ED50 values of 16 mg/kg and 40 mg/kg, respectively. In a rat model of 
collagen-induced arthritis (rCIA) it significantly inhibited pathogenic anti-rat collagen antibodies, 
paw swelling, inflammatory cell infiltration, proteoglycan loss and joint erosion when dosing 
started, before disease onset and full efficacy was also observed with low doses (3 mg/kg bid). In 
a therapeutic setting when 131 was administered when significant paw swelling was present, a 
dose of 10 mg/kg bid significantly ameliorated disease parameters.103 Currently 131 is undergoing 
Phase II/III studies for Activated PI3Kδ syndrome and Primary Sjögren syndrome.106 
Xin et al. reported on the synthesis of a range of 4-anilinequinazoline derivatives as PI3K 
inhibitors designed as a fast follower approach. 
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Scheme 8: 2,8-Disubstituted pyrido[3,2-d]pyrimidine inhibitors 
 
Changing the aromatic linkage present in the Novartis compound 132 generated a new series of 
6-aryl substituted 4-anilinquinazoline derivatives (Scheme 8), which resulted in the identification 
of 133 (PI3K IC50 = 9.3 nM). 133 demonstrated similar anti-proliferative profiles to idelalisib in 
several human B cell lines (e.g RPMI-8226 IC50 = 6.61 M; idelalisib IC50 = 5.49 M).107 Further 
studies, changing the aniline group for less lipophilic moieties resulted in the identification of 134 
(PI3K IC50 = 2.7 nM; PI3K IC50 = 25.6 nM; PI3KIC50 = 263.8 nM; PI3K IC50 = 174.2 nM).108 
134 showed significant potent anti-proliferative activity against human B cell line Ramos (IC50 = 
0.57 M), moderate anti-proliferation against RPMI-8226 (IC50 = 4.34 M) and SU-DHL-6 (IC50 
= 4.55 M), but no activity against Raji (IC50 > 10 M). 
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Hei et al. reported on a series of 4,6-disubstituted quinazoline derivatives, as typified by 135, 
which displayed high potency against PI3K enzymes (PI3K IC50 = 465 nM, PI3K IC50 = 37 
nM) and anti-proliferative activities against both HCT-116 (IC50 = 0.51 M) and MCF-7 (IC50 = 
2.10 M) and could efficaciously inhibit tumor growth in a mice S-180 model.109 In a similar series 
of compounds, Xin et al. demonstrated that 136 had good PI3K enzyme activity (PI3K IC50 = 
9.3 nM) and showed similar anti-proliferative profiles to idelalisib in human B cell lines [e.g. 
RPMI-8226 cells IC50 = 6.61 M, idelalisib 5.49 M].110 Zhang et al. reported on 137, a potent 
PI3K/mTOR dual inhibitor which significantly inhibit Class I PI3Ks (PI3K IC50 = 0.87 nM; 
PI3K IC50=  3.9 nM; PI3K IC50 = 1.7 nM; PI3K IC50 = 8.4 nM), mTOR (IC50 = 10 nM) and 
phosphorylation of pAkt(Ser473) at low nanomolar level.111 Moreover, 137 displayed high 
potency in an anti-proliferative assay in PC-3 cells (IC50 = 80 nM) and showed acceptable in vivo 
pharmacokinetic properties in mice after oral administration at 5 mg/kg as a crystalline suspension 
in 0.5% methylcellulose [ CL = 0.42 L/h/kg, Vd, = 1.0 L/kg, plasma terminal half-life (T1/2, 1.6 
h)]. Mah et al. reported the identification of 4‑phenoxyquinoline based inhibitor for L1196M 
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mutant of anaplastic lymphoma kinase as typified by 138 discovered by a fragment growing 
strategy.112 138 exhibited significant anti-proliferative effects on H2228 CR crizotinib-resistant 
cells by decreasing PI3K/AKT and MAPK signaling. Fan et al. highlighted compound 139 with 
potent anti-proliferative activity without cytotoxicity to human normal cells. 139 was reported to 
be selective for PI3Ka (IC50 = 13.6 nM. Selectivity ~10-fold) and, in a western blot assay, 138 
demonstrated inhibition of cell proliferation via suppression of PI3K kinase activity (IC50 of 13.6 
nM) and subsequently blocked PI3K/Akt pathway activation in HCT116 cells.113  
 
7,9-Disubstituted-2-morpholino-4H-pyrido[1,2-a]pyrimidin-4-one-based inhibitors – 
evolution of AZD6482 and AZD8186 
TGX-221 (140) was disclosed as a selective PI3K inhibitor by Kinaacia Ply Ltd, a spin out 
from Monash University, and has served as the inspiration of several drug discovery programs 
looking for potent and selective PI3K inhibitors (Scheme 9). 
 
Scheme 9. Evolution of 7,9-disubstituted-2-morpholino-4H-pyrido[1,2-a]pyrimidin-4-one-
based inhibitors 
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Scientists at GSK separated the enantiomers by chiral HPLC and discovered that the biological 
activity resided in one enantiomer, with the (R)-enantiomer 141 (PI3K IC50 = 6 nM) being ~30-
fold more potent than the (S)-enantiomer (PI3K IC50 = 200 nM), suggesting that the aniline 
plays an important role in the interaction with PI3K.114 It was suggested that imadazo[1,2-a]-
pyrimidine-5(1H)-one, with a N-1 substituted benzyl group, would be a replacement scaffold and 
SAR demonstrated that a 2, 3-disubstituted benzyl group was optimal for balancing potency and 
PI3K isoform selectivity 142 (PI3K = 1 nM; PI3K = 2M; PI3K = 8 nM; PI3K = 1 M), 
as well as demonstrating potent cell growth inhibition (EC50 = 0.14 M) against a PTEN-
deficient breast cancer cell line (MDA-MB-468). In a follow on publication, the core 
imadazo[1,2-a]-pyrimidine-5(1H)-one was changed to a 1,2,4-triazolo[1,5-a]pyrimidin-7(3H)-
one with similar activity, 143 (PI3K = 1.5 nM; PI3K = 4 nM), as well as demonstrating good 
cell growth inhibition (EC50 = 0.1 M) against a PTEN-deficient breast cancer cell line (MDA-
MB-468). Substituting the morpholine ring with a 2-methyl group substantially increased 
potency and cell-based activity 144 (PI3K = 0.3 nM; PI3K = 4 nM; EC50 = 0.5 nM). 
Unfortunately, the series of compounds suffered high rat clearance and was not progressed.115 In 
light of the poor rat metabolic stability, a core change to a new thiazolopyrimidinone series was 
evolved.114 Once more extensive SAR studies identified 145 (PI3K = 0.6 nM; PI3K = 2.5 M; 
PI3K = 20 nM; PI3K = 0.79 M; cell: MDA-MB-468 pAKT IC50 24 nM; proliferation gIC50 = 
0.103 M). Importantly, 145 showed good pharmacokinetics (mouse PK CL 29.6 mL/min/kg); 
Vdss 2.8 L/kg; F 49%) and progressed to a PTEN-deficient PC-3 prostate carcinoma xenograft 
mouse model, where it was dosed once-daily for 21 days at 100 and 300 mg/kg, demonstrating 
complete tumor growth inhibition relative to vehicle treated mice, with no effect on body weight. 
However, the authors conclude by stating that other unknown activities of PI3K may be 
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contributing to the effects on tumor growth. However, these studies represented a significant 
milestone towards validating PI3K as a potential target for proliferative disorders. 
Scheme 10. Chemical modifications on 146 to deliver AZD8186 a PI3K Inhibitor for use in 
treating patients with advanced solid tumors with PTEN or PIK3CB mutations that are metastatic 
or cannot be removed by surgery 
 
Once more taking inspiration from 141 and 146 (AZD6482), Barlaam et al. reported on the 
discovery of 9-(1-anilinoethyl)-2-morpholino-4-oxo-pyrido[1,2-a]pyridine carboxamides as 
selective PI3Kinhibitors for the treatment of PTEN-deficient tumors.116 With an aim of 
reducing lipophilicity and balancing PI3K enzyme and cellular activity through increasing 
permeability, a series of 6-substituted carboxamides were synthesized which resulted in the 
identification of 147 (PI3K IC50 = 5 nM; PI3K IC50 = 0.075 M; PI3K IC50 = 32 nM; PI3K 
IC50 = 0.51 M; cell: MDA-MB-468 pAKT IC50 = 3 nM, mouse PK CL = 82 mL/min/kg; F = 
31%)). 147, a compound with low/medium metabolic stability, showed profound 
pharmacodynamic modulation of phosphorylated Akt in a PC3 prostate tumor xenograft after a 
single oral dose. In addition, 148 (PI3K IC50 = 7 nM; PI3K = 0.34 M; PI3K IC50 = 45 nM; 
PI3K IC50 = 3.0 M; cell: MDA-MB-468 pAKT IC50 = 34 nM, mouse PK CL = 74 mL/min/kg; 
F = 35%) demonstrated significant inhibition of tumor growth in the PC3 prostate xenograft 
model after chronic oral dosing. In order to address the low/medium metabolic stability, improve 
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solubility and increase bioavailability, a reduction in lipophilicity was explored, where the core 
was changed to a 2-morpholino-4-oxo-4H-chromene-6-carboxamide scaffold to generate, after 
extensive SAR studies, 149 (PI3K IC50 = 4 nM; PI3K IC50 = 35 nM; PI3K IC50 = 12 nM; 
PI3K IC50 = 0.675 M; cell: MDA-MB-468 pAKT IC50 = 3 nM, mouse PK CL = 77 
mL/min/kg; F = 18%) (Scheme 10).117 149 proved to be efficacious for p-Akt in PTEN-deficient 
PC3 prostate tumor bearing mice after oral administration and showed complete inhibition of 
tumor growth in a mouse PTEN-deficient PC3 prostate tumor xenograft model. 149 was selected 
as a clinical candidate for patients with advanced castrate-resistant prostate cancer (CRPC), 
squamous non-small cell lung cancer (sqNSCLC), triple negative breast cancer (TNBC) and 
known PTEN-deficient / mutated or PIK3CB mutated / amplified advanced solid malignancies as 
a monotherapy and in combination with vistusertib or abiraterone acetate. Further clinical studies 
are on-going. 
Marshall et al. reported on further SAR evaluation of pyrido[1,2-a]pyrimidinone-based class 1 
PI3K inhibitors (Scheme 11).118 Extensive SAR, such as replacement of the group X of by CH2O 
and CH2S decreased both potency and selectivity as well as constraining the group X with 
NHSO2, NHCO or CONH moieties confirming the structural requirements for these “T-shaped” 
inhibitors.117 Interestingly, in this report the N-methyl analogue 150 showed the best potency 
(PI3K IC50 = 20 nM) but was not tested in a cell-based assay. 
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Scheme 11. Pyrido[1,2-a]pyrimidinone-based class 1 PI3K inhibitors 
 
 146 is an ATP-competitive PI3Kβ inhibitor and the first human target validation of PI3Kβ 
inhibition with 2 was reported following a 3 h infusion of seven different doses of 146; a wide 
separation between anti-thrombotic effect and bleeding was observed, demonstrating that 
previous pharmacodynamic findings in dog translated well to man. Whereas 146 was well 
tolerated in man, a weak but significant concentration-dependent increase in plasma insulin and 
corresponding homeostasis model analysis (HOMA) index was recorded. In the plasma 
concentration range tested, it was suggested that such an effect could be ascribed to the 
compound’s ability to inhibit PI3Kα (IC50 = 0.87 μM). In addition, 146 had a short plasma half-
life (5–43 min) due to high metabolic clearance and a relatively small distribution volume (40–
68 L).117 Thus the pharmacokinetic and pharmacodynamic profile of 146 might limit its use to 
parenteral administration in situations where a low bleeding risk is desirable. Giordanetto et al. 
reported  fragment-based drug discovery approaches 119,120 to reduce the PI3K inhibitory 
activity through investigating the requirement of the aromatic carboxylic acid, the linking group 
to the aniline and the incorporation of a group to improve water solubility. This extensive SAR 
resulted in 151 (PI3K IC50 = 100 nM; PI3K IC50 = 3.5 M; PI3K IC50 = 0.4 M; PI3K IC50 
= 83 M; dog PK CL = 8 mL/min/kg; F = 31%) as a novel orally bioavailable PI3K inhibitor.  
151 inhibited platelet activation in plasma and whole blood, was highly soluble and 
metabolically stable. Furthermore, no significant inhibition of Cyp450 enzymes and ion channels 
involved in cardiac function was recorded. Efficacy versus bleeding in anaesthetized dogs 
showed 151 elicited a concentration-dependent inhibition of platelet aggregation ex vivo (EC80 = 
0.69 ± 0.06 μM), which well predicted its inhibition of thrombosis in vivo (EC80: 0.6 ± 0.05 μM). 
Importantly, no significant increase in bleeding time and blood loss was recorded at the observed 
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maximum compound concentration (24.1 ± 2.3 μM).  Finally, no significant increase of the 
homeostasis model analysis (HOMA-index) from baseline was apparent at the maximum 
compound concentration (20.4 ± 2.1 μM). Therefore, the safety margin to compound 
concentrations resulting in full antithrombotic effect was acceptable and 151 was selected as a 
preclinical candidate for further development (Scheme 12).121 
 
Scheme 12. Extensive SAR to deliver 151 
 
Starting from a high throughput screening campaign, Certal et al. identified 152 as an interesting 
lead due to its selectivity for PI3K versus other PI3K isoforms (PI3K IC50 42-2133 nM in 
various screens and >10 M on PI3K). Chemistry to exchange the potentially labile amide 
bond with heterocyclic replacements gave 153 (PI3K IC50 = 158 nM) and 154 (PI3K IC50 = 
82nM) and further SAR optimization resulted in 155 (PI3K IC50 = 99 nM; PI3K IC50 = 1395 
nM and >10 M on PI3K), a compound with adequate in vitro pharmacokinetic properties 
and was shown to potently inhibit Akt phosphorylation in PTEN-deficient PC3 prostate 
carcinoma cell line when dosed at 300 mg/kg b.i.d. for 9 days.122 
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In a continuation of their studies, Certal et al. reported on the identification of the clinical 
candidate 156 (SAR260301), a low molecular weight compound (MW 354 cLogP 1.5) with 
improved physicochemical and in vitro pharmacokinetic properties (PI3K IC50 = 23 nM; PI3K 
IC50 = 1.5 M; PI3K IC50 = 0.47 M; PI3K IC50 = >10 M; dog PK CL = 0.4 L/h/kg; F = 
67%). The first X-ray co-crystal structure of p110β with the selective inhibitor 156 bound to the 
ATP site demonstrated the “T-shaped” nonplanar binding mode. The X-ray showed that the 
morpholine oxygen accepts a H-bond from Val-848 in the hinge region.123 The aniline generates 
an induced fit in the P-loop at the top of the ATP binding site creating a lipophilic pocket lined 
with Met771 and Trp781 and this was the reason for the -isoform selectivity (Figure 11).  
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Figure 11. Binding of 156 to the ATP binding site of p110 (PDB 4BFR) – visualized in PyMol 
 
Compound 156 demonstrated significant in vivo activity in a mouse UACC-62 xenograft model 
and entered phase I/Ib clinical trials in patients with advanced cancer where 156 had an 
acceptable safety profile, but exposure sufficient to inhibit the PI3K pathway was unachievable 
because of rapid clearance, and clinical development was terminated.124  
Benzoxazepin-based PI3K Inhibitors 
In 2011, Staben et al. identified a benzopyran-based inhibitor 157 from a HTS.125  
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Compound 157 exhibited reasonable potency for PI3KIC, however the 
physicochemical properties were not ideal (cLogP = 4.1, LE = 0.39, LipE = 2.5, MW = 356). 
Due to the structural novelty of the scaffold, a SAR study was initiated where the aryl substituent 
on the aniline amide revealed the importance of the ortho-halogen for PI3K activity. 
Additionally, a crystal structure of 158 (PI3Kα = 0.108 µM) indicated that the N-methylaniline 
amide bound in a cis-fashion in the activity pocket, and that the hinge binding interaction of the 
pyran oxygen was suboptimal, and could be potentially improved upon through ring expansion. 
This led to a 7-membered ring with a 4-fold increase in potency (PI3K = 0.024 µM) and 
subsequent expansion to an 8-membered ring, 159, reduced potency drastically (>10 µM). 
Comparison of the crystal structures of 157 and 159 confirmed a shorter hydrogen bond and 
better angle for interaction with the hinge Val882 (Figure 12). Although potency had increased, 
the rate of clearance proved consistently high across the series of analogs. A metabolite ID 
experiment in human hepatocytes revealed hydrolysis of the aniline amide and an oxidative 
metabolite resulting from demethylation, aromatic oxidation and glucoronindation of the aniline. 
Para-substitution with an electron withdrawing polar amide 161 (GNE-614) reduced 
lipophilicity (clogP = 2.7), blocked para-oxidation, and decreased clearance in rat (36 
mL/min/kg). Compound 161 exhibited good potency towards the class I PI3Ks (PI3Kα IC50 = 
4.6 nM, PI3Kβ IC50 = 60 nM, PI3Kγ IC50 = 5 nM, PI3Kδ IC50 = 1.7 nM) and was relatively 
inactive against mTOR (IC50 = 530 nM). However, 161 showed only a moderate PK profile: rat 
(CL = 36 mL/min/kg, F = 50%, AUC = 39 µM/h), mouse (CL = 15 mL/min/kg, F = 28%, AUC 
= 330 µM/h), and dog (CL = 5 mL/min/kg, F = 120%, AUC = 17 µM/h) and was found to inhibit 
DNA-PK (IC50 = 6 nM), a structurally similar counter target.  
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Figure 12. The X-ray crystal structures of 157 showing a shorter hydrogen bond and better angle 
for interaction with the hinge Val882 (PDB 3R7R) 
 
In a follow-up paper, Staben et al. aimed to improve the upon the PK profile of 161 by 
replacing the metabolically liable cis-N-methyl anilide with an appropriate bioisostere. After 
extensive SAR they discovered that replacing the aryl group with an alkyl group was not 
tolerated. However, replacement with heteroaryl groups led to the discovery of 162 (PI3Kα IC50 
= 4 nM) which showed improved properties for further optimization (rat CL = 13 mL/min/kg), 
AUC = 5.7 - 17.8 µM/h).126 
 
Following the discovery of 162, Staben et al. set out to further decrease the lipophilicity of the 
series by modification of the thiophene.127 In addition, replacement of the thiophene would 
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remove the potential oxidative metabolism of this group. After identifying a number of suitable 
heteroaryl groups the group opted to select the thiazole, 163 for further development. 163 was 
highly potent towards the class I PI3Ks (PI3Kα IC50 = 0.27, PI3Kβ IC50 = 15 nM, PI3Kγ IC50 = 
0.55 nM, PI3Kδ IC50 = 0.61 nM), although they observed that potency towards PI3Kβ was 
consistently lower with specific substitutions at the 8-position of the benzoxepin. They 
hypothesized that this was due to a different conformation (in PI3Kβ) of the tryptophan residue 
that makes up the tryptophan shelf in the case of PI3Kδ. Compound 163 showed a suitable PK 
profile for further advancement as it had low clearance and high bioavailability in rodents (rat 
CL = 5.4 mL/min/kg, F = 83%, mouse CL = 9.5 mg/mL/kg, F = 110%), acceptable PK in dog 
(CL = 14 mL/min/kg, F = 22%) and moderate predicted clearance in human (hepatocyte Clp = 
12 mL/min/kg). In addition, 163 showed modest tumor growth inhibition in an MCF7-neo/HER2 
xenograft breast cancer model and activity against counter targets were also reduced (mTOR 
IC50 >4.3 µM and DNA-PK IC50 = 0.34 µM). 
With 163 showing only modest tumor growth inhibition in a MCF7-neo/HER2 xenograft 
breast cancer model despite being highly potent and exhibiting a moderate PK profile, Staben et 
al. aimed to increase the unbound exposure by further reducing the lipophilicity. An extensive 
screen of heteroaryl isosteres was performed, with focus on lowering the lipophilicity, leading to 
the discovery of 164 (GDC-0032, clogD 2.5). Compound 164 showed good activity towards the 
class I PI3Ks, with decreased PI3Kβ activity (PI3Kα IC50 = 0.29 nM, PI3Kβ IC50 = 9.1 nM, 
PI3Kγ IC50 = 0.12 nM, PI3Kδ IC50 = 0.97 nM). In addition, against a panel of 235 kinases, only 2 
(not including the Class I PI3Ks) exhibiting greater than 50% inhibition at 10 M concentration: 
C2β (80.4%), and Vps34 (69.9%). 164 also had a good PK profile, exhibited low in vivo 
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clearance in rat with high oral bioavailability (F = 99%). After toxicological and safety 
evaluations, 164 was progressed to clinical trials for PI3K-related cancers.128 
 
Having only reported pan or so-called β-sparing benzoxepins, in 2016, Heffron et al. moved 
the focus of their program towards the development of selective PI3Kα inhibitors. 129 At the 
onset of their PI3Kα program, a crystal structure of one of their benzoxepin inhibitors was 
obtained, revealing two residues unique to the α-isoform, Gln859 and His855. From molecular 
modelling evidence the team decided to target Gln859 in order to gain selectivity towards PI3Kα. 
Extensive SAR, and monitoring of torsion angle at the 8-position, focused on optimizing 
hydrogen bonding with Gln859. This led to the discovery of 165 (GDC-0326), where the primary 
amide makes 3 concerted hydrogen bonds with Gln859 (Figure 13). 165 is a PI3Kα-selective 
inhibitor (PI3Kα IC50 = 0.2 nM, ⍺/β = 133, ⍺/γ = 51, ⍺/δ= 20) and showed a comparable PK 
profile to 164 and was selected for further study, although it has not yet progressed into the clinic 
at the time of writing.  
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Figure 13. 165 X-ray crystal structure in PI3K where the primary amide makes 3 concerted 
hydrogen bonds with Gln859 (PDB 5DXT) 
 
In their most recent publication, Safina et al. used their previous experience with the design of 
selective PI3Kδ inhibitors in order to build-in PI3Kδ selectivity into the benzoxepin core.130 
Since the benzoxepin core was a result of ADME optimization it possessed favorable drug-like 
properties and therefore this was an attractive endeavor. They discovered 166 as a PI3Kδ-
selective inhibitor (PI3Kδ IC50 = 1.9 nM, δ/⍺ = 113) through interaction via the tryptophan 
shelf.130 Compound 166 had low lipophilicity (clogD 1.29), yet maintained good permeability 
(MDCK A to B = 10 × 10−6 cm/s). 
Amino thiazole and aminobenzthiazole urea-based inhibitors 
 
Scheme 13. Discovery of the urea-based inhibitor 171 from early HTS of a kinase focused library 
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In 2012, scientists from Cellzome reported 167 (PI3Kα pIC50 < 4, PI3Kβ pIC50 < 4, PI3Kγ 
pIC50 = 5.4, PI3Kδ pIC50 = 4.5) and 168 (PI3Kα pIC50 = 4.9, PI3Kβ pIC50 = 4.7, PI3Kγ pIC50 = 
5.7, PI3Kδ pIC50 = 5.2) as hits from an HTS of a kinase focused library of 16000 compounds 
(Scheme 13).131–133 SAR around the core led to 169 (CZC19945, PI3Kα pIC50 = 5.6, PI3Kγ pIC50 
= 7.6, PI3Kδ pIC50 = 5.8). Further SAR on the central core led to 170 (CZC24832, PI3Kα pIC50 
< 5, PI3Kγ pIC50 = 7.6, PI3Kδ pIC50 = 5.1). 170 showed moderate PK properties in mouse (CL = 
11.5 mL/min/kg, F = 37%), showed no inhibition of hERG up to 100 µM, no CYP inhibition and 
was negative in the Ames test. In addition, 170 demonstrated efficacy in a chronic model of 
inflammation, although poor aqueous solubility (5 µg/mL) made pre-clinical development 
problematic. Crystallographic studies show that these compounds bound to the hinge region of 
PI3Kγ via the donor/acceptor motif of the triazolopyridine with the pyridine sulphonamide 
interacting with the activity pocket. In a further publication, Ellard et al. detailed more SAR at 
the solvent exposed region, leading to PI3Kγ/δ compounds such as 171 (PI3Kα pIC50 6.4, PI3Kγ 
pIC50 = 8.4, PI3Kδ pIC50 = 7.8, PI3K pIC50 = 6.3), although poor physicochemical properties 
precluded them from oral absorption.134 
 
In parallel, Oka et al. identified 172 as a hit in their HTS with excellent enzymatic potency 
(PI3Kγ IC50 = 5 nM). Through structural modification, struggling initially with permeability 
issues, they developed 173 (PI3Kγ IC50 = 10 nM, α/γ = 4) and 174 (PI3Kγ IC50 = 3 nM, α/γ = 5). 
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However, although both demonstrated improved permeability leading to improved cellular 
potency, they showed low selectivity over PI3Kγ.135 In a later publication, it was reported that 
the de-acetylated version of 173 was positive in the Ames test.136 Although the de-acetylated 
product was not found to be a major metabolite, they sought to mitigate mutagenic risk by 
replacing the oxazole ring with more -electron deficient heterocycles. This led to the 2-amino-
5-oxadiazolyl thiazole 175, where both the acetylated and de-acetylated analogs were negative in 
the Ames test. Being approximately equipotent in terms of PI3Kγ potency to 174, they were able 
to explore 175 further, leading to the discovery of 176 (TASP0415914, PI3Kγ IC50 = 29 nM). 
176 exhibited a better PK profile, showed no CYP inhibition and was progressed to in vivo 
studies in a mouse collagen-induced arthritis model and was effective in a dose-dependent 
manner. 
 
Also, in 2012, Bruce et al. revealed 177 as a hit from a HTS targeting PI3Kγ.137 A docking 
study involving 177 showed that the thiazole nitrogen and amide hydrogen form a bidentate 
donor–acceptor pair with the hinge region, and the sulfonamide interacts with the activity pocket. 
They observed that residues lining the binding pocket were less conserved and hypothesized that 
isoform selectivity might be achievable by extending or replacing the acyl moiety with diverse 
substituents to exploit these differences. After developing a method of thiazole synthesis 
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amenable to automation, they were able to generate approximately 400 analogs with 
replacements for the acyl moiety. Most of these compounds were found to be either inactive or 
weak pan-PI3K inhibitors. However, 3 types of amines were identified which led to potent 
isoform selective inhibitors. For example, (S)-pyrrolidine carboxamides such as 178 (NVS-PI3-
1, PI3Kα Ki = 0.005 µM, PI3Kβ Ki = 2.0 µM, PI3Kγ Ki = 0.53 µM, PI3Kδ Ki = 0.22 µM) and 
179 (NVS-PI3-2, PI3Kα IC50 = 0.04 µM, PI3Kβ IC50 = 22.94 µM, PI3Kγ IC50 = 1.19 µM, PI3Kδ 
IC50 = 0.54 µM) were the optimal compounds. A structurally related benzothiazole was shown to 
be selective towards PI3Kα, due to the carboxamide making favorable interactions with the non-
conserved Gln859 of PI3Kα. Aminopropionic acid derivatives such as 180 (NVS-PI3-3, PI3Kα 
Ki = 0.15 µM, PI3Kβ Ki = 0.34 µM, PI3Kγ Ki = 1.02 µM, PI3Kδ Ki = 0.004 µM), 181 (NVS-
PI3-4, PI3Kα Ki = 1.89 µM, PI3Kβ Ki = 0.25 µM, PI3Kγ Ki = 0.088 µM, PI3Kδ Ki = 0.74 µM) 
and 182 (NVS-PI3-5, PI3Kα Ki = 1.40 µM, PI3Kβ Ki = 0.32 µM, PI3Kγ Ki = 0.036 µM, PI3Kδ 
Ki = 0.47 µM) led to PI3Kδ-selective (180) and PI3Kγ-selective (181 and 182). The authors 
suggested that the PI3Kδ and PI3Kγ selectivity was most likely derived from interactions 
between the terminal functional groups of the urea side chain and non-conserved amino acids at 
the outer edge of the binding site. Additionally, all examples in the series were much less potent 
towards PI3Kβ than the other isoforms. However, the PK properties of 178-182 were not 
adequate for further progression, but this work led to some interesting observations towards 
selective inhibitors. 
Following this in 2013, Furet et al. disclosed the discovery of the PI3Kα selective inhibitor 
183, Alpelisib (NVP-BYL719).138 Addressing the poor PK and isoform selectivity within the 
series to date, extensive SAR studies around 178 led to the discovery of 183 (PI3Kα IC50 = 0.005 
µM, PI3Kβ IC50 = 1.2 µM, PI3Kγ IC50 = 0.25 µM, PI3Kδ IC50 = 0.29 µM). Crystallographic 
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evidence of 183 in complex with PI3Kα shows that 183 exhibited its excellent selectivity 
towards PI3Kα by exploiting the non-conserved Gln859 of PI3Kα. 183 had a suitable PK profile 
(rat CL = 10 mL/min/kg, Vss = 1.9 L/kg) and showed no significant CYP or related-kinase 
inhibition, and was progressed to clinical development.  
 
In 2014, Collier et al. analyzed the crystal structure of PIK-93 and observed that there was 
sufficient space in the ATP binding pocket to allow for a ring fusion of the thiazole into a 
benzothiazole where hinge binding could be achieved through the donor-acceptor motif of the 
nitrogen atoms of the aminobenzothiazole. 184 (PI3Kγ Ki = 0.004 µM, α/γ =1, β/γ = 10, and δ/γ 
= 3) and 185 (PI3Kγ Ki = 0.002 µM, α/γ = 66, β/γ = 21, and δ/γ = 61) were compounds which 
exhibited isoform selectivity towards PI3Kγ.139 After obtaining an X-ray crystal structure for 185 
in PI3Kγ (Figure 14, PDB 4PS3), they hypothesized that this selectivity was a result of two non-
conserved residues within the binding site. The first is Ala885, which is unique to PI3Kγ.  In 
PI3Kα, β, and δ this is a serine residue where the OH of serine is involved in hydrogen bonding 
with the hinge valine residue. They proposed that introduction of urea functionality allows for 
the urea carbonyl to form an additional hydrogen bond to the hinge valine, which in-turn breaks 
the serine-valine hydrogen bond, freeing up the OH group thereby introducing a steric clash with 
the lipophilic side chain. This steric clash is unfavorable in the anti-targets and does not happen 
in the case of PI3Kγ. The second non-conserved residue is Gly829, a glutamic acid residue in 
PI3Kα. This aids selectivity over PI3Kα upon increasing the length of the terminal alkyl chain. 
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These compounds were not progressed further, however they were useful in determining 
important residues for identifying new approaches for PI3K isoform selectivity.  
 
Figure 14. X-ray crystal structure of 185 in PI3Kγ, demonstrating new key interactions 
generating isoform selectivity (PDB 4PS3)  
 
To improve the overall physicochemical properties (as typified by 185), Collier et al. aimed to 
reduce the overall lipophilicity in combination with increasing the fraction of Sp3 atoms (FSp3) 
within the series.140 In order to accomplish this, they replaced the central benzothiazole core with 
a thiazolopiperidine, leading to 186 (PI3Kγ Ki = 0.002 µM, α/γ = 228, β/γ = 105, and δ/γ = 395). 
In 186 they suggested that incorporating fluorine atoms onto the terminal alkyl chain increased 
selectivity markedly through increasing affinity for PI3Kγ, due to a C−F···C=O interaction with 
Thr827. Additionally, they suggested that the increase in selectivity was driven by a favorable 
interaction of the acidic methine proton of the fluoroethyl group with Glu814, a residue unique to 
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PI3Kγ. Compound 186 showed no significant inhibition in a screen of structurally related 
kinases.  
 
Figure 15. Strategy employed to reduce the number of H-bond donor groups to aid CNS 
penetration and compound 187. 
In a recent publication, Come et al. disclosed further refinement of the core structure with a 
view to increasing blood-brain barrier penetration. The authors highlighted the general difficulty 
in designing CNS-penetrant kinase inhibitors due, in part, to the property space characteristics of 
the ATP-competitive kinase inhibitors, where hydrogen bond donor moieties are essential 
pharmacophoric elements required to bind to the kinase hinge region. They proposed a very 
elegant solution where an isoindolinone carbonyl group would provide a hydrogen bond acceptor 
to the backbone NH of the hinge residue Val882 and, in addition, an aromatic proton would be 
positioned in place of the urea NH donor (Figure 15). Further functionalization gave 187 as a 
selective, brain penetrant inhibitor of PI3Kγ (PI3Kγ Ki = 4 nM, α/γ = 60, β/γ = 10, and δ/γ = 14). 
187 was an orally bioavailable compound (rat PK CL = 20 (mL/min)/kg, F = 100%, T1/2 = 5.1 h) 
that showed efficacy in murine experimental autoimmune encephalomyelitis (EAE), a preclinical 
model of multiple sclerosis.141 
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Pemberten et al. discovered 188 (PI3Kγ pIC50 = 6.8) from a HTS. They showed that 
methylation of the acetamide 189 led to a large reduction in potency, suggesting that the 
acetamido-substituted isoxazole was the hinge binding motif.142 SAR to replace the isoxazole 
with amino heterocycles that are typical kinase hinge-binding motifs lead to replacement of the 
isoxazole with a thiazole, 190 (R)-enantiomer PI3Kγ pIC50 = 8.9. Failing to co-crystallize 
inhibitors of the series in PI3Kγ, the team looked to co-crystallize inhibitors in PI3Kδ. 
Successfully crystallizing 190 within PI3Kδ they confirmed the aminothiazole forms hydrogen 
bonds to the hinge residue Val828 and that the carbonyl of the lactam interacts with Lys779. The 
N-alkyl tail is oriented perpendicular to the isoindolinone core and extends deep into the ATP-
binding pocket. An interesting observation was that removal of the N-alkyl group led to a 100-
fold decrease in PI3Kγ activity and a corresponding 15-fold increase in PI3Kα potency, 
suggesting that PI3Kγ selectivity seems to originate from the N-alkyl tail extending deep into the 
ATP-binding pocket. Compound 190 exhibited poor properties for oral administration due to a 
combination of poor solubility, high in vitro clearance and high lipophilicity. Introduction of a 
sulfone led to the discovery of 191, with excellent isoform selectivity (PI3Kα pIC50 < 4.5, PI3Kβ 
pIC50 < 4.5, PI3Kγ pIC50 = 8.1, PI3Kδ pIC50 = 6.0) and good bioavailability (F = 51%) and low 
in vivo clearance (rat 6.3 mL/min/kg). In a kinase screen only related kinases C2β (84%) and C2γ 
(71%) showed significant inhibition at 10 M concentration. In a rat LPS-induced acute 
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inflammation model, oral administration of 191 resulted in a dose-dependent inhibition of airway 
neutrophilia in rats. 
PI3K dual pharmacology compounds 
 
Qian et al. observed synergistic effects between PI3K inhibitors and HDAC inhibitors and 
therefore synthesized a novel series of dual-acting PI3K and HDAC inhibitors by incorporating 
HDAC inhibitory functionality into a PI3K inhibitor pharmacophore.143 They incorporated the 
morpholine-pyrimidine core from 85 and 70 for PI3K inhibition and the hydroxamic acid from 
SAHA (Vorinostat), LBH-589 (Panobinostat) and JNJ-16241199 for HDAC inhibition to 
produce 192 (CUDC-907).144,145 They reported that 192 displayed potent anticancer activity in 
both cultured cancer cells and xenograft models and may offer therapeutic benefits in multiple 
cancers, through broad signaling network disruption. 192 is currently in phase I and II clinical 
trials. In a similar fashion, Chen et al. once more combined the PI3K and HDAC 
pharmacophores to generate a series of dual inhibitors typified by 193 (PI3K⍺ = 28 nM, HDAC1 
= 1.1 nM, HDAC6 = 4.2 nM). Compound 193 demonstrated target modulation in cancer cell 
lines and in mice bearing MV4-11 and HepG2 tumors and, in particular, showed significant 
single agent oral efficacy in hypervascular liver cancer models (e.g., HepG2, HuH-7, and 
Hep3B) and was well-tolerated.146 
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Ding et al. reported novel 4-aminoquinazolines as dual target inhibitors of EGFR-
PI3KBased on the structural similarity to omipalisib and gefitinib,compound 194 was shown 
to possess reasonable PI3K activity (IC50 = 317 nM) in combination with very high EGFR 
activity (IC50 = 2.4 nM). Compound 194 could induce cell cycle arrest in G1 phase and apoptosis 
in BT549 cells. The western blot assay indicated that 194 inhibited the proliferation of BT549 
cell through EGFR and PI3Ka/Akt signaling pathway, suggesting that compound 194 could be a 
potential dual inhibitors of EGFR and PI3K.147 
 
Pujala et al. reported a range of pyrazolopyrimidine derivatives, such as 195, as dual inhibitors 
of Bruton’s tyrosine kinase (BTK, IC50 = 32 nM) and PI3Kδ (IC50 = 16 nM). 195 had a 
reasonable mouse pharmacokinetic profile [10 mg/kg PO, CL = 0.59 L/h/kg, Vz = 3.44 L/kg, 
plasma terminal half-life = 1.3 h, F = 40%)]. No in vivo results were shown for the compound.148    
Conclusion and perspective comment: 
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The PI3K pathway has attracted enormous industrial and academic interest as a therapeutic 
target for clinical conditions, such as cancer, diabetes and asthma. Idelalisib was the first PI3K 
inhibitor approved by the US Food and Drug Administration (FDA) and is utilized in the 
treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma and 
follicular lymphoma.149 However, the use of idelalisib may come with toxicities that are distinct 
from the side effects of immunochemotherapy and, as such, co-dosing strategies with steroids are 
currently being investigated in the clinic. 150,151 Subsequently, copanlisib was approved for 
relapsed follicular lymphoma in patients who have received at least two prior systemic 
therapies.152 In addition, there is a wealth of PI3K agents currently in clinical development (38 at 
this present time), which target various combinations of the PI3K isoforms. While idelalisib has 
proven to be efficacious for patients, unexpected infectious and autoimmune toxicities have 
demonstrated the need for careful development and monitoring of new agents. 
The phosphatidylinositol 3-kinase family consists of highly conserved enzymes that are part of 
the intracellular PI3K/Akt/mammalian target of rapamycin (mTOR) signaling axis. As such, 
early medicinal chemistry strategies concentrated on the discovery of non-selective PI3K 
inhibitors. However, the identification of “propeller-shaped” PI3K inhibitors signaled a step-
change in the design of isoform selective PI3K inhibitors. This led to the identification of 
idelalisib, the first FDA-approved PI3K inhibitor.  
Concerns over isoform toxicity has led to groups exploring structural modification to 
synthesize compounds with PI3K isoform selectivity through subtle change in chemical 
structure.  This led to the explosion of structural variation, with many changes to the core of the 
molecules, mainly to secure intellectual property, but has also, in some cases leading to subtle 
changes in isoform selectivity. In general, the initial pan PI3K inhibitors suffered from poor 
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physicochemical properties, such as poor solubility and permeability from the combination of 
multiple aromatic rings and lack of sp3 carbons leading to compounds with poor pharmacokinetic 
properties.153,154 These early issues were rapidly solved by medicinal chemists, through 
decreasing lipophilicity and adding ionizeable groups to deliver compounds with excellent 
permeability and good oral pharmacokinetic properties. Drug delivery has also been considered, 
with various groups exploring the design of compounds with improved pharmacokinetics for 
topical lung delivery, thus removing some of the safety issues involved with systemic exposure 
of the high affinity inhibitors.  
Running in parallel with the discovery of the propeller shaped inhibitors, the identification of 
“flat-shaped” pan PI3K inhibitors has resulted in the delivery of many potent clinical candidates. 
However, their inherent lack of 3 dimensional structure resulted in compounds with higher 
lipophilicity leading again to poor water solubility. These physicochemical properties resulted in 
compounds with reduced cellular potency and off-target toxicity in pre-clinical studies. Once 
more concerns over pan-PI3K inhibition has, through careful consideration of ligand-bound X-
ray structures, led to the creative design of inhibitors with good to excellent isoform selectivity. 
However, these highly selective inhibitors have generally gained their selectivity at a 
consequence of increased molecular weight resulting, in the case of PI3K inhibitors, movement 
towards topical (i.e. inhaled) delivery.  
Bivalent or dual pharmacology inhibitors have been disclosed, where secondary pharmacology 
has been built into the original PI3K core scaffold, such as the dual PI3K/HDAC inhibitors and 
more recently EGFR-PI3K dual inhibitors utilizing solvent-exposed positions of the PI3K 
scaffold to incorporate the secondary pharmacology.  
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Finally, it should be noted the extremely positive effect that ligand-bound X-ray 
crystallography has had on the design and synthesis on new isoform selective PI3K inhibitors. 
Outputs from these studies has enabled medicinal chemistry groups to thoroughly explore 
structural diversity in pursuit of gaining freedom to operate in a very congested and narrow field. 
In addition, the often non-predictive subtle targeting of specific residues inducing isoform 
selectivity was made possible through information gleaned from multiple ligand-bound X-ray 
crystal data, once more highlighting the importance of structure based drug design for to increase 
isoform selectivity. 
In conclusion, it is disappointing that many PI3K inhibitors have not met their true clinical 
potential due to: the absence of reliable and effective biomarkers, the limited efficacy as single 
agents and the lack of development of rational therapeutic combinations, off-target effects, and 
suboptimal therapeutic exposures.7 Therefore, it is hoped that with regard to current PI3K 
inhibitors in late-stage clinical trials, the identification of appropriate efficacy biomarkers and the 
development of optimal combination regimens will lead to future successful FDA drug 
approvals. 
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